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Summary 
 Regulatory T cells (Treg cells) are essential for maintaining immune homeostasis. 
However, how Treg cells exert their function in tissue specific environments is often unknown. 
We have found hydroxyprostaglandin dehydrogenase (Hpgd), the major Prostaglandin E2 
(PGE2) metabolizing enzyme, to be significantly upregulated in Treg cells compared to 
conventional T cells (Tconv). In the murine system, this upregulation is especially pronounced 
in the visceral adipose tissue (VAT), a prostaglandin-rich environment. 
 Furthermore, we could show that through the metabolism of PGE2 into 15-keto-PGE2 
Hpgd enhances the suppressive capabilities of Treg cells in an, at least partially, Pparγ-
dependent manner. In vivo, we found that Hpgd-deficient Treg cells were less efficient in 
preventing the onset of both DSS-induced and adoptive transfer colitis, further indicating that 
Hpgd plays a role in the suppressive capacity of Treg cells. However, analysis of the 
transcriptome of these Hpgd-deficient Treg cells did not differ significantly from Hpgd-
competent Treg cells, indicating that the observed changes are due to the extrinsic effect 
caused by the loss of the enzymatic function of Hpgd. 
 When analyzing the VAT of aged animals with Hpgd-deficient Treg cells, we could 
detect an influx of non-functional Treg cells as well as an accumulation of pro-inflammatory 
macrophages and an increase in adipocyte size. Furthermore, while we could neither detect a 
change in body or organ weight of these animals, nor a change in motility, food and water 
intake, or respiration, we could observe impaired metabolic signaling. Aged animals with 
Hpgd-deficient Treg cells respond less to insulin and glucose challenge and show a reduction 
in insulin signaling. 
 When subjecting animals with Hpgd-deficient Treg cells to a high fat diet (HFD), we 
could not detect a difference in weight gain when compared to wildtype littermate control 
animals. Even though we could detect a slight decrease in insulin responsiveness in animals 
on a HFD with Hpgd-deficient Treg cells, no difference in the VAT-resident immune cell 
population or in any other metabolic parameters could be observed.  
 Additionally, in peripheral blood from human type II diabetes (T2D) patients we 
observed a dysregulation of the Treg cell population as well as a decrease in HPGD expression 
in these cells compared to healthy, age-matched controls. Taken together, these data indicate 
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that both in humans and in the murine system, HPGD expression in Treg cells might be 
involved in metabolic regulation. 
 Finally, we analyzed the role of the Treg cell specific transcription factor mesenchyme 
homeobox 1 (MEOX1) for HPGD expression. We found that MEOX1 is highly upregulated 
in human Treg cells, especially after stimulation with interleukin (IL) 2. Furthermore, we could 
show that while MEOX1 expression, like HPGD, is regulated by FOXP3, a loss of MEOX1 
does not affect HPGD expression, thus disproving our hypothesis that HPGD may be 
regulated by the transcription factor MEOX1.  
Taken together, we could describe that HPGD is an important mediator of Treg cell 
suppression, independently of MEOX1. We found that a Treg cell specific deletion of Hpgd in 
the mouse leads to a dysregulation of the metabolism, and that HPGD levels are significantly 
decreased in Treg cells isolated from the peripheral blood of T2D patients compared to Treg 
cells isolated from healthy subjects.  
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1. Introduction 
1.1. The Immune System 
The immune system is our primary defense mechanism against invading pathogens 
and can be divided into two interacting branches: the innate and the adaptive immune system. 
The innate immune system is older in evolutionary terms and consists of those elements of the 
immune system which mount an immediate response (Brubaker et al., 2015). The adaptive 
immune system, on the other hand, is slower to respond but, since it consists of antigen-
specific reactions of T- and B- lymphocytes, it is more precise than the innate immune system 
and has been associated with the development of immunological memory (Bonilla and 
Oettgen, 2010). Despite the clear distinction between the two branches of the immune system, 
there is a significant amount of interaction between the innate and adaptive immune system. 
For instance, dendritic cells (DCs), as members of the innate immune system, respond to 
environmental cues but also have the capability to capture, process, and present antigens and 
thus activate the adaptive immune system (Parkin and Cohen, 2001; Steinman, 2006). 
1.1.1. Adaptive Immunity 
The adaptive immune system consists mainly of B-lymphocytes, which produce 
antigen-specific antibodies (Hoffman et al., 2016), and antigen-specific T cells. T cells 
develop in the thymus and can be divided into two major subsets: cytotoxic T lymphocytes 
(CTLs) and T helper (TH) cells. These cells differ in their function and, due to the differential 
expression of the co-receptors cluster of differentiation (CD) 4 and 8 on TH and CTLs, 
respectively, in their ability to bind to either major histocompatibility complex (MHC) class II 
or class I molecules (Broere et al., 2011; Miceli and Parnes, 1991).  
After priming in secondary lymphoid organs, CTLs are activated by T-cell receptor 
(TCR) signaling once they encounter foreign or infected cells. This results in the induction of 
apoptosis in the opposing cell either via the exocytosis of perforin and granzymes or in a 
caspase-dependent manner (Broere et al., 2011).  
TH cells, on the other hand, recognize MHC class II molecules which are only 
expressed by professional antigen presenting cells (APCs), such as macrophages or DCs 
(Dustin et al., 2006). APCs can take up antigens in peripheral tissues and present the antigen 
on MHC II molecules. Upon migrating to secondary lymphoid tissues, APCs encounter TH 
cells and activate them in an antigen-specific manner. Once activated, TH cells differentiate 
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into a variety of different TH-cell subgroups depending on the microenvironment and are 
empowered with pathogen-specific reactivity reflected in the production of a variety of 
different cytokines (Luckheeram et al., 2012; Reinhardt et al., 2006). Activated TH cells are 
involved in many immunological processes, such as the activation of macrophages, B cells 
and CTLs (Broere et al., 2011; Castellino and Germain, 2006; Mills and Cambier, 2003). 
A third subgroup of T cells has been described, which is at the interface of innate and 
adaptive immunity, namely natural killer T (NKT) cells. NKT cells function independently of 
MHCs. Rather, they rely on the CD1d molecule, which presents glycolipid antigens and, like 
CTLs, NKT cells have cytotoxic functions (Godfrey et al., 2004). NKT cells can be divided 
into different subgroups depending on the expression of CD4 and CD8 and differ in their 
respective cytokine production (Godfrey et al., 2004, 2010). 
Finally, γδ T cells comprise the last group of T cells. Unlike the CTLs or TH they do 
not express the α and β chains of the TCR but γ and δ TCR chains and therefore recognize a 
different set of antigens. While αβ TCRs require antigen-presentation via MHCs and 
recognize mainly non-self antigens, γδ TCRs are activated independently of MHCs and 
recognize not only pathogenic but also stress antigens. γδ T cells can target cells either 
directly by inducing cytotoxicity or through the production of a variety of cytokines which, in 
turn, lead to the activation of other immune cells (Bonneville et al., 2010; Lawand et al., 
2017) 
1.1.2. Regulatory T cells 
TH cells can be divided into two subgroups: regulatory T (Treg) cells and conventional 
T (Tconv) cells. Tconv cells consist of all TH subgroups, which lead to the activation of the 
immune system, including for example TH1 and TH17 cells (Reinhardt et al., 2006), while Treg 
cells are vital for the maintenance of peripheral tolerance by acting both on their environment 
and on other immune cells in an immunomodulatory manner (Sakaguchi et al., 1995; Vignali 
et al., 2008). If Treg cells can no longer function properly, this results in the development of 
autoimmunity including the induction of several different autoimmune diseases in the mouse, 
such as arthritis, gastritis, type I diabetes and pancreatitis (Asano et al., 1996; Papiernik et al., 
1997; Sakaguchi et al., 1995; Suri-Payer et al., 1998).  
Treg cells can be characterized by the constitutive expression of the interleukin (IL) 2 
receptor -chain, CD25, and the transcription factor forkhead-box-protein P3 (FOXP3). 
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FOXP3 is necessary for tissue homeostasis as a disruption of FOXP3 leads to the 
development of severe autoimmune diseases, such as the immunodysregulation 
polyendocrinopathy enteropathy X-linked (IPEX) syndrome in humans (Vignali et al., 2008). 
In the mouse, a disruption of Foxp3 leads to the development of the so-called ‘scurfy’ 
phenotype which is characterized by a lack of Treg cells and the onset of an ultimately lethal 
autoimmune disease (Brunkow et al., 2001; Fontenot et al., 2003), caused by hyperactive TH 
cells as indicated by increased expression of the activation markers CD69 and CD44 
(Fontenot et al., 2003). This indicates that Foxp3 is important for the immunomodulatory 
function of Treg cells. Further, it was shown that when transducing naïve TH cells with Foxp3, 
these cells develop a suppressive function and exhibit an inhibitory effect on cell proliferation 
(Hori et al., 2003). All in all, this demonstrates that Foxp3 plays a vital role in the 
development and maintenance of Treg cells (Vignali et al., 2008). 
Treg cells exert their immunosuppressive function in a variety of manners. It has been 
described that Treg cells can interfere with the immune response of other lymphocytes (Sojka 
et al., 2008). Presence of Treg cells has also been shown to prematurely interrupt the activation 
of Tconv cells, finally resulting in the downregulation of IL-2 mRNA (Sojka et al., 2005) and 
inducing a completely different transcriptional program compared to uninhibited Tconv cells 
(Sukiennicki and Fowell, 2006). 
However, the exact mechanism through which Treg cells function is a matter of debate. 
It has been described that Treg cells function both in a contact-dependent and contact-
independent manner (Vignali et al., 2008). Treg cells have been shown to secrete inhibitory 
cytokines, such as the transforming growth factor (TGF)-β, IL-10 and IL-35 (Asseman et al., 
1999; Collison et al., 2007; Powrie et al., 1996). TGF-β is important for lymphocyte 
homeostasis by influencing the regulation of their chemotaxis, activation and survival (Li et 
al., 2005). Furthermore, Tconv cells which, due to a mutation of their TGF-β receptor, cannot 
signal via TGF-β are not impacted by Treg cell suppression (Fahlén et al., 2005). However, 
Treg cells do not need to produce TGF-β themselves, indicating that Treg cells may influence 
other cells to produce anti-inflammatory cytokines, like TGF-β and IL-10, to exert their 
suppressive function (Fahlén et al., 2005; Kullberg et al., 2005). IL-10 has also been 
implicated in the suppression of Tconv cell mediated inflammation and expansion (Sojka et al., 
2008). Interestingly, while IL-10 is necessary for the inhibition of antigen-experienced cells, 
IL-10 is not necessary for the inhibition of naïve T cells (Asseman et al., 2003). The cytokine 
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IL-35 leads to the suppression of Tconv cell proliferation both in vitro and in vivo and the 
expression of IL-35 in T cells imparts suppressive properties to these cells (Collison et al., 
2007).  
Furthermore, Treg cells also seem to exert their function by disrupting the metabolism 
of other cells. This is achieved either by competing with other cells for growth factors and 
cytokines or by deregulating the adenosine metabolism (Vignali et al., 2008). 
Treg cells, unlike Tconv cells, constitutively express the IL-2 receptor CD25 and it has 
been shown that in co-cultures, Treg cells deprive Tconv cells of IL-2 (Barthlott et al., 2005; de 
la Rosa et al., 2004). Nonetheless, IL-2 deprivation is most likely not the only mechanism in 
which Treg cells modulate the immune reaction of Tconv cells. This reasoning is supported by 
the fact that the gene expression profile of Tconv cells which are undergoing IL-2 deprivation 
differs greatly from that of Tconv cells which are being suppressed by Treg cells (Sukiennicki 
and Fowell, 2006).  
Apart from the competition for IL-2, it has also been described that Treg cells compete 
for cytokines both in vivo and in vitro and that the deprivation of these cytokines leads to 
apoptosis of Tconv cells (Pandiyan et al., 2007). However, this mechanism is probably not Treg 
cell specific but could rather be induced by any T cell which expresses high levels of cytokine 
receptors on its cell surface (Ge et al., 2004).  
Furthermore, it has been shown that the expression of the ectoenzymes CD39 and 
CD73 on the cell surface of Treg cells leads to the production of adenosine, which suppresses 
Tconv cell function by activating the adenosine receptor A2A on the surface of activated Tconv 
cells (Deaglio et al., 2007). This, in turn, also favors the generation of Treg cells as A2A 
signaling inhibits IL-6 signaling, which would lead to the differentiation into pro-
inflammatory T cells, and instead leads to the secretion of TGF-β, thus promoting the 
immunosuppressive milieu (Vignali et al., 2008; Zarek et al., 2008). Another manner in which 
Treg cells interrupt adenosine signaling in Tconv cells is by directly introducing cyclic 
adenosine monophosphate (cAMP), an inhibitor of both proliferation and IL-2 synthesis in T 
cells, into the cells through gap junctions, thus reducing Tconv cell functionality (Bopp et al., 
2007). 
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In addition to modulating the immune response by secreting inhibitory cytokines and 
competing for proliferation-supporting cytokines, Treg cells also inhibit via cell-cell contacts. 
Cell-surface bound TGF-β (Nakamura et al., 2001) as well as cytolytic molecules have been 
implicated in the cell-contact dependent suppressive function of Treg cells. Treg cells can lyse 
cells (Cao et al., 2007), induce apoptosis in B cells through Fas-Fas ligand interaction 
(Janssens et al., 2003) and LAG-3, a CD4 homologue which is expressed on the cell surface 
of activated Treg cells, is implicated in the Treg cell suppressor activity towards Tconv cells 
(Huang et al., 2004). Furthermore, cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is 
constitutively expressed by Treg cells, also contributes to the suppressive function of Treg cells 
by influencing T-cell receptor hyposignaling, proliferation, and anergy of target cells (Tai et 
al., 2012). 
However, none of the described mechanisms alone are sufficient to explain the 
functionality of Treg cells. Rather, it is assumed that Treg cells function in all of these – and 
possibly more, as of yet undescribed – manners to exert their function (Sojka et al., 2008; 
Vignali et al., 2008).  
1.1.3. Tissue resident Regulatory T cells 
In recent years, it has been described that Treg cells differ in their phenotype and 
function depending on the tissue they reside in (Luu et al., 2017; Zhou et al., 2015), such as a 
distinct population of Treg cells in the muscle expressing the growth factor amphiregulin are 
vital for muscle repair (Burzyn et al., 2013). Furthermore, it has been described that 
disturbing a unique skin-resident Treg cell population expressing high levels of both CD103 
and C-C motif chemokine receptor 4 (CCR4) leads to increased inflammation in the skin of 
these animals indicating that upsetting the balance of tissue-resident Treg cells leads to the 
induction of tissue-specific inflammation (Ali and Rosenblum, 2017; Sather et al., 2007) .  
1.1.3.1. Visceral Adipose Tissue Regulatory T cells 
Another subset of tissue resident Treg cells are visceral adipose tissue (VAT) resident 
Treg cells, first described by Feuerer et al. in 2009 (Feuerer et al., 2009). In contrast to cells 
from the lymphoid compartment, where Treg cells make up approximately 10-15% of the TH-
cell subgroup, in the VAT the TH-cell fraction consists of approximately 40-60% of Treg cells. 
Like Treg cells isolated from the spleen, these cells are effective in suppressing Tconv cell 
proliferation and retain most of the classical Treg cell markers such as CD25, Foxp3 and Ctla-4 
(Feuerer et al., 2009).  
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Analysis of gene expression of VAT-resident Treg cells revealed a significant 
difference between the expression pattern of these VAT resident Treg cells compared to Treg 
cells of lymphoid organs, such as the spleen or lymph nodes (LNs). For instance, VAT-
resident Treg cells express higher amounts of genes involved in leukocyte migration and 
extravasation such as CCR2, CCR9 and CXCL10, among others, indicating that VAT-
resident Treg cells may be recruited from the periphery based on unique expression patterns of 
chemokine and cytokine receptors (Cipolletta et al., 2011; Feuerer et al., 2009; Zhou et al., 
2015). 
Furthermore, the anti-inflammatory cytokine IL-10, as well as several genes 
downstream of the IL-10 receptor, are highly upregulated in VAT-resident Treg cells, 
suggesting that VAT-resident Treg cells play an important role in preventing the development 
of inflammation in the VAT and the induction of inflammation-associated obesity-related 
metabolic disorders (Feuerer et al., 2009). 
VAT-resident Treg cells have also been implicated in the control of the metabolism of 
mice. Obese animals showed significantly lower VAT-resident Treg cell numbers than lean 
littermate control animals in three different mouse models. Moreover, a direct correlation 
could be observed between  the number of Treg cells in the VAT and insulin resistance: 
increased VAT-resident Treg cell numbers lead to a corresponding increase in insulin 
sensitivity (Feuerer et al., 2009). 
1.2. Prostaglandins in the Immune System 
Prostaglandins (PGs) are oxygenated polyunsaturated fatty acids containing a 
cyclopentane ring structure and are potent lipid mediators which play an important role in the 
immune system (Phipps et al., 1991). PGs are metabolized from arachidonic acid, which is a 
component of the eukaryotic cell membrane, by cyclooxygenase-1 and -2 (COX-1 and COX-
2), thus forming PGG2, which can be further metabolized by different synthases into a variety 
of other PGs (Bergstroem et al., 1964; Van Dorp et al., 1964) (Figure 1). These are classified 
from A to J, according to the structure of the cyclopentane ring (Kawahara et al., 2015).  
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Figure 1: Metabolism of Prostaglandins (PGs) 
Arachidonic Acid is metabolized by COX-1 or 2 to PGH2 and subsequently to PGG2, which is 
further metabolized by different synthases to PGD2, PGF2α, PGE2, PGI2 and TXA2. PGE2 is 
further metabolized by HPGD into 15-keto PGE2 which can be further reduced by PTGR1 or 2 
into 13,14-Dihydro-15-keto-PGE2. COX-1/2, Cyclooxygenase 1/2; PGH2, Prostaglandin H2; 
PGG2, Prostaglandin G2; PGD2, Prostaglandin D2; PGF2α, Prostaglandin F2α; PGE2, 
Prostaglandin E2; PGI2, Prostaglandin I2; PTGR1/2, Prostaglandin Reductase 1/2; TXA2, 
Thromboxane A2. (Figure adapted from Kawahara et al., 2015; Simmons et al., 2004) 
PGs have long been known to play a role in the immune system. For instance, they 
have been shown to affect lymphocyte proliferation (Franks et al., 1971) and thymocyte 
differentiation (Singh and Owen, 1975). The best described and most abundant of the PGs is 
PGE2 (Sreeramkumar et al., 2012). Upon production, PGE2 is released from the cell and acts 
in an auto- or paracrine manner via the cell-type specific PGE2 receptors EP1, EP2 and EP3 
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(Narumiya, 1994). The three receptors are G-protein coupled receptors which respond to 
PGE2 in different manners: signaling via EP1 leads to an increase of free, intracellular Ca
2+
 
via Gq, EP2 signaling increases cAMP via Gs  while EP3 decreases cAMP via Gi signaling 
(Buchanan et al., 2006; Fujino et al., 2003; Honda et al., 2006; Regan, 2003) Later, a fourth 
receptor, EP4, was identified which signals in a similar manner to EP2 and differs only in its 
ability to activate phosphatidylinositol 3 kinase (PI3K) signaling (Kawahara et al., 2015; 
Sreeramkumar et al., 2012). However, it has been shown that PGE2 does not only act in an 
auto- or paracrine manner but that it can also be taken up by cells via the prostaglandin uptake 
transporter where it can either act on intracellular EP receptors (Bhattacharya et al., 1998) or 
interact directly with other signaling molecules, thereby leading to a variety of different 
biological effects (Lalier et al., 2011). 
PGE2 plays a role in many biological functions. Next to its role in fertility, 
gastrointestinal integrity, and the regulation of blood pressure, PGE2, like most other PGs, is 
also an important mediator of the immune response (Legler et al., 2010; Ricciotti and 
FitzGerald, 2011). However, the exact manner in which PGE2 acts within the immune system 
is still not fully resolved. 
Indicative of its role in the immune system is the observation that the presence of pro-
inflammatory stimuli can lead to the expression of PGE synthases (Filion et al., 2001), thus 
leading to an increased production of PGE2 in pro-inflammatory settings. Interestingly, PGE2 
has been implicated not only in pro- but also in anti-inflammatory situations. PGE2, in its role 
as an important pro-inflammatory mediator, leads to an increase in cytokine and chemokine 
production (Funk, 2001). Furthermore, when PGE2 is administered to mice it causes increased 
vasodilation, increased local blood flow and hyperalgesia, leading to increased leukocyte 
infiltration. Thus, PGE2 is involved in the development of all four hallmarks of acute 
inflammation: redness, swelling, pain, and edema (Omori et al., 2014; Sreeramkumar et al., 
2012). Conversely, it has been shown that PGE2 suppresses IL-1β mediated expression of 
cytokines and chemokines such as IL-8 and Macrophage Inflammatory Protein 1 (MIP-1) and 
the production of tumor necrosis factor alpha (TNF-α) and Interferon gamma (IFN-γ), thus 
exerting an anti-inflammatory role (Takayama et al., 2002). Likewise, stimulating DCs with 
PGE2 leads to an upregulation of suppressive molecules, inhibiting T-cell proliferation, thus 
further cementing the immunosuppressive role of PGE2 (von Bergwelt-Baildon et al., 2006). 
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Furthermore, it has been shown that all four EP receptors are expressed on the surface 
of TH cells (Chemnitz et al., 2006), indicating that PGE2 can play an important role in TH cell 
biology. As a matter of fact, whole transcriptome analysis of TH cells stimulated with PGE2 
showed that the majority of the genes downstream of the TCR are inhibited by PGE2 
stimulation, leading to the conclusion that PGE2 interferes with TCR signaling, thus inhibiting 
the activation of TH cells (Chemnitz et al., 2006). Moreover, PGE2 has been implicated in the 
induction of T-cell anergy (Mannie et al., 1995).  
Other data implicate PGE2 in the differentiation and maintenance of several different 
TH-cell subgroups.  The presence of PGE2 favors the differentiation of  TH cells into TH2 cells 
over TH1 cells by inhibiting the production of TH1 but not TH2 cytokines (Betz and Fox, 
1991). Furthermore, PGE2 has been shown to enhance TH17-cell differentiation by increasing 
the expression of the classical TH17-cytokine profile by EP2 signaling and inhibiting the 
expression of immunomodulatory cytokines through EP4 signaling (Boniface et al., 2009).  
Additionally, there are conflicting reports indicating that PGE2 may either be involved 
in (1) the suppression of Treg cell development by EP2 signaling, leading to the 
downregulation of classical Treg cell proteins such as CTLA-4 and GITR, as well as the 
production of the anti-inflammatory cytokine IL-10 (Li et al., 2017) or (2) in enhancing the 
development of Treg cells by upregulating key genes of the Treg cell signature, such as FOXP3 
(Bryn et al., 2008; Sharma et al., 2005).  
However, due to these contradictory findings, the exact mechanism in which PGE2 
influences T-cell biology still needs to be further elucidated. 
1.2.1. 15-hydroxyprostaglandin dehydrogenase 
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (HPGD) is the key enzyme of 
the PGE2 metabolism (Figure 1). HPGD oxidizes the prostanoid 15-hydroxyl group to a 
ketone, thus generating the signaling molecule 15-keto-PGE2, a metabolite which can no 
longer bind to the EP receptors, consequently abrogating EP receptor signaling (Tai et al., 
2002), and which is rapidly degraded into the unstable metabolite 13,14-Dihydro-15-keto-
PGE2 in the presence of PTGR1 or 2 (Fitzpatrick et al., 1980). Furthermore, a reciprocal 
regulation with COX-2 seems to indicate that, together with COX-2, HPGD is involved in the 
regulation of PG levels (Tai et al., 2006; Tong et al., 2006).  
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HPGD was first characterized in 1964, when it was observed that PGE1 was converted 
into its metabolites in lung homogenates unless the homogenate was boiled, thus indicating an 
enzymatic reaction is responsible for the metabolism of the PG (Samuelsson, 1964). 
Subsequently, HPGD was isolated from swine lung (Anggård, 1966) and has since been found 
to be expressed ubiquitously in mammalian tissues (Bergholte and Okita, 1986; Braithwaite 
and Jarabak, 1975; Chang et al., 1990; Lee and Levine, 1975). 
A second version of HPGD exists: NADP+-dependent HPGD type II. However, 
HPGD type II appears to be less active than the type I enzyme (Krook et al., 1993). 
Furthermore, NADP+-dependent HPGD is far less specific for prostaglandins. Moreover, the 
two enzymes are only about 20% homologous, indicating an early evolutionary divergence 
between the two enzymes (Wermuth, 1992). Additionally, the physiological function of 
HPGD type II is unclear since it does not seem to metabolize PGs in vivo as the KM value for 
all prostaglandins is too high (Tai et al., 2006). A possible alternative substrate for HPGD 
type II may be quinines (Wermuth, 1992; Wermuth et al., 1986). Furthermore, compared to 
HPGD type I,  HPGD type II is relatively lowly expressed in immune cells, including Treg 
cells, with the highest expression observed in naïve TH cells (Heng et al., 2008). 
1.2.1.1. The role of HPGD in disease 
Even though it has long since been known that HPGD is expressed in monocytes 
(Maddox and Serhan, 1996) and that its expression is reduced in tumor-infiltrating 
macrophages (Eruslanov et al., 2009), no functional role for HPGD has been described in 
immune cells. 
However, HPGD has been implicated in several different types of cancer. An 
inhibition of HPGD leads to increased inflammation and decreased tumor formation (Arima et 
al., 2019). HPGD is markedly downregulated in colonic epithelial cells of colon cancer 
patients compared to healthy controls and in mice Hpgd expression inhibits tumor formation 
in the colon (Myung et al., 2006; Yan et al., 2004). A similar observation has been made in 
breast cancer: the HPGD promoter is methylated in around 30% of primary tumors leading to 
epigenetic silencing of HPGD in breast cancer. Furthermore, an upregulation of HPGD in 
mice leads to decreased tumor formation while a downregulation of the enzyme correlates 
with increased cell proliferation (Wolf et al., 2006). In line with this, it has been shown that an 
inhibition of HPGD can lead to tissue regeneration following liver injury(Zhang et al., 2015). 
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Interestingly, it has also been shown that HPGD, through the metabolism of PGE2 into 15-
keto-PGE2, can inhibit the growth of hepatocellular carcinoma (Lu et al., 2014). 
Next to its role in cancer inhibition, HPGD is also necessary for reproduction. This is 
unsurprising as PGs control both ovulation and menstruation and play a role in the 
establishment of pregnancy and initiation of labor (Arosh et al., 2004a, 2004b; Challis et al., 
1999; Kang et al., 2005). It has been suggested that HPGD is the key enzyme which controls 
PGE2 levels during pregnancy, especially during the recognition of pregnancy (Parent et al., 
2006; Tai et al., 2006). Thus, a loss of HPGD can lead to the induction of pre-term birth in 
mice (Kishore et al., 2017; Roizen et al., 2008). Furthermore, a loss of HPGD leads to several 
congenital defects such as the induction of primary hypertrophic osteoarthropathy (Uppal et 
al., 2008) and a patent ductus arteriosus (Coggins et al., 2002). 
1.3. Interplay of Metabolism and the Immune System 
Metabolism is a complex system of catabolic, anabolic and transformative reactions 
within a cell necessary to maintain life in any organism. In this context, insulin signaling is a 
vital pathway which regulates both glucose and lipid metabolism (Boucher et al., 2014; Saltiel 
and Kahn, 2001). 
1.3.1. The Role of Insulin Signaling in the Metabolism 
Insulin signaling is vital to maintain glucose homeostasis and is mainly influenced by 
fasting states (Baeshen et al., 2014). Insulin is produced in the pancreas by beta cells as a 
single polypeptide. Increased blood glucose levels following the digestion of carbohydrates 
lead to the release of insulin and the subsequent uptake of glucose into cells. Insulin signaling 
via the insulin receptor (IR) induces cellular processes that increase the usage or storage of 
glucose in the cell (Baeshen et al., 2014; DeFronzo et al., 2015).  
When insulin binds to the IR, the receptor forms a dimer and the intracellular tyrosine 
kinase domain auto-phosphorylates (Kasuga et al., 1982), leading to recruitment and 
phosphorylation of scaffold proteins, mainly insulin receptor substrate (IRS) 1 and 2. Whereas 
IRS1 is important for growth and peripheral insulin signaling, IRS2 is involved in the control 
of body weight, glucose homeostasis and fertility (Schubert et al., 2003). Association with the 
phosphorylated IRS molecules leads to the activation of PI3K which phosphorylates 
phosphatidylinositol (4,5)-bisphosphate (PIP2), an inositol phospholipid of the plasma 
membrane, into phosphatidylinositol (3,4,5)-trisphosphate (PIP3). This phosphorylation leads 
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to the recruitment of both 3-phosphoinositide-dependent protein kinase 1 (PDK-1) and the 
kinase AKT and subsequent phosphorylation and activation of AKT by PDK-1. AKT has 
many downstream substrates such as BCL2 Associated Agonist Of Cell Death (BAD), which 
plays an important role in cell survival, or Glycogen Synthase Kinase (GSK) 3β, which 
regulates growth and glycogen synthesis (Figure 2) (Boucher et al., 2014; White, 2003). 
Insulin signaling varies depending on the cell type; for instance insulin is most important for 
glucose uptake in muscle cells, and, to a lesser degree, adipocytes (DeFronzo et al., 2015), 
while osteocytes are largely unaffected by insulin signaling (Sheng et al., 2014). 
 
 
Figure 2: Insulin Signaling via AKT. 
Insulin binding to the insulin receptor (IR) induces autophosphorylation of the receptor 
which, in turn, leads to the recruitment and phosphorylation of the insulin receptor 
substrates (IRS) 1 – 4. These phosphorylated substrates activate the phosphatidylinositol 
(4,5)-bisphosphate (PIP2), an inositol phospholipid of the plasma membrane, into 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 recruits the 3-phosphoimositide-
dependent protein kinase 1 (PDK-1) and the kinase AKT. Phosphorylation of AKT by PDK-1 
leads to the activation of AKT and subsequent downstream signaling is important for 
protein synthesis and induces gene transcription of important genes for survival and cell 
cycle progression. Furthermore, AKT signaling is vital for the cell metabolism as it controls 
gluconeogenesis, glucose transport as well as both glycogen and lipid synthesis. (Figure 
adapted from Boucher et al., 2014) 
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If insulin signaling is disrupted, the resulting hyperglycemia can lead to a host of 
different diseases, including but not limited to dyslipidemia, hypertension, cardiovascular 
disease, stroke, kidney disease, female infertility, neurodegeneration and the development of 
diabetes (White, 2003). Globally, metabolic disorders, such as type II diabetes (T2D), are on 
the rise. According to the World Health Organization, 60 million people were afflicted with 
diabetes in the European Region as of 2010. Worldwide, 3.4 million people annually die of 
diabetes, a number that is estimated to double by 2030 (World Health Organization (WHO), 
2010). These statistics do not differentiate between type I diabetes and T2D, yet as 
approximately 90% of all diagnosed cases of adult diabetes are T2D, the current rise in 
diabetes is most likely due to an increase in T2D (DeFronzo et al., 2015; NCD Risk Factor 
Collaboration (NCD-RisC), 2016). This has led to a refocusing of research on metabolism and 
the underlying signaling pathways, such as insulin signaling (Boucher et al., 2014). 
1.3.1.1. Type II Diabetes 
Diabetes can be divided into three subgroups: gestational diabetes, Type I diabetes and 
T2D. Gestational diabetes occurs in approximately 5% of all pregnancies. During pregnancy, 
due to hormonal changes, maternal tissues become increasingly insensitive to insulin leading 
to an increase of maternal insulin secretion of about 200% in order to maintain glucose 
homeostasis. Gestational diabetes develops when insulin secretion is not upregulated and thus 
the insulin sensitivity is not compensated for (Barbour et al., 2007; Kampmann et al., 2015). 
Type I diabetes, on the other hand, is an autoimmune disease leading to the destruction 
of beta cells in the pancreas. Thus, not enough insulin is produced, leading to hyperglycemia 
and related symptoms (Katsarou et al., 2017).  
The most prevalent form of diabetes, however, is T2D which accounts for an 
estimated 90% of all cases of diabetes (DeFronzo et al., 2015). The occurrence of T2D is 
heavily influenced by lifestyle: a sedentary lifestyle, smoking, alcohol consumption, and an 
unhealthy diet are known risk factors for T2D (Hu et al., 2001). As such, obesity has been 
shown to contribute to more than 50% of T2D cases (DeFronzo et al., 2015). 
T2D patients exhibit insulin insensitivity caused by insulin resistance and reduced 
insulin production (Kahn, 1994) caused by a combination of genetic and environmental 
influences. Insulin resistance can be induced by the activation of different protein kinases 
which interfere with the canonical insulin signaling pathway thus exploiting negative 
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feedback mechanisms to inhibit insulin signaling, resulting in insulin insensitivity (DeFronzo 
et al., 2015; Olokoba et al., 2012). Beta cell dysfunction, on the other hand, can also be 
induced by many different factors, such as increased oxidative or endoplasmatic reticulum 
stress as well as increased inflammation. In healthy humans, oxidative glucose metabolism in 
beta cells leads to an increase of intracellular ATP causing a closure of potassium channels. 
This, in turn, leads to an influx of calcium and the subsequent depolarization of the cell 
membrane, inducing the exocytosis of insulin. However, if the oxidative potential is somehow 
disturbed, the entire process is disrupted leading to a dysregulation of insulin production, 
which can lead to the induction of T2D (DeFronzo et al., 2015) 
During fasting, glucose and glucagon levels rise. In patients suffering from T2D, these 
levels can no longer be suppressed with a meal due to increasing insulin insensitivity and 
inadequate insulin levels. This leads to hyperglycemia and related acute symptoms, such as 
weakness, weight loss and blurred vision (DeFronzo et al., 2015; Olokoba et al., 2012) and 
retinopathy, nephropathy and neuropathy as long-term consequences of insulin resistance 
(White, 2015). 
1.3.2. Peroxisome Proliferator-Activated Receptor γ Signaling 
The nuclear receptor peroxisome proliferator-activated receptor-γ (PPAR-γ) is a 
transcription factor which is mainly expressed in brown and white adipose tissue and plays a 
vital role in insulin sensitivity, adipocyte differentiation, and in lipid homeostasis (Ahmadian 
et al., 2013; Staels and Fruchart, 2005). When PPAR-γ is activated by ligand binding, it 
recruits co-activator proteins and heterodimerizes with the retinoid-X receptor. These 
heterodimers can bind to genomic peroxisome proliferator-response elements, thus promoting 
or repressing gene expression (Ahmadian et al., 2013; Staels and Fruchart, 2005). 
Most genes downstream of PPAR-γ are relevant for glucose homeostasis and fatty acid 
uptake and storage but also inflammation. For this reason, Ppar-γ has been described as a 
metabolic master-regulator (Ahmadian et al., 2013; Staels and Fruchart, 2005). A further 
indication for its role in the metabolism is that thiazolidinediones, a class of PPAR-γ ligands, 
have found use as antidiabetic drugs (Lehmann et al., 1995).  
Most PPAR-γ ligands are anti-inflammatory in nature. Thiazolidinediones, for 
example, inhibit pro-inflammatory cytokine production in activated lymphocytes, monocytes 
and microglia (Jiang et al., 1998; Lombardi et al., 2008; Schmidt et al., 2004). Furthermore, 
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both human and murine studies showed that a stimulation with thiazolidinediones leads to a 
PPAR-γ-dependent upregulation of anti-inflammatory processes (Luo et al., 2006; Yu et al., 
2009). 
Another ligand of PPAR-γ, which has been identified is 15-keto-PGE2, the main 
metabolite generated by the enzymatic activity of HPGD. In 3T3-L1 cells, 15-keto-PGE2 has 
been shown to act as a PPAR-γ ligand, thereby increasing 3T3-L1 adipogenesis and activating 
other PPAR-γ downstream targets. Furthermore, overexpressing one of the 15-keto-PGE2 
metabolizing enzymes, Prostaglandin Reductase (PTGR) 1, leads to the degradation of 15-
keto-PGE2 and the ablation of PPAR-γ signaling. Conversely, overexpressing HPGD leads to 
increased generation of 15-keto-PGE2 from PGE2 and thus increased PPAR-γ signaling (Chou 
et al., 2007), thus implicating the enzymatic activity of HPGD in the induction of PPAR-γ 
signaling. 
1.3.3. Metabolic Signaling and VAT-resident Treg cells 
1.3.3.1. Insulin signaling and VAT-resident Treg cells 
VAT-resident Treg cells contribute to the prevention of obesity-related diseases. It has 
been described that VAT-resident Treg cells confer anti-inflammatory properties and that these 
successfully improve insulin sensitivity and decrease the severity of other metabolic disorders 
caused by obesity (Zhou et al., 2015). 
Furthermore, it has been described that female animals are protected against metabolic 
disorders induced by feeding of a high caloric diet by increasing the levels of VAT-tissue 
resident Treg cells (Ingvorsen et al., 2017; Pettersson et al., 2012), while a loss of VAT-
resident Treg cells causes a decrease in insulin sensitivity and an upregulation of inflammation 
in the VAT (Cipolletta et al., 2011). Moreover, the adoptive transfer of Treg cells decreased 
insulin resistance in obese mice (Ilan et al., 2010), indicating that VAT-resident Treg cells 
might play a role in delaying the onset of obesity-related diseases. 
Conversely, the genetic prevention of the development of the population of VAT-
resident Treg cells leads to a marked improvement of age related insulin resistance in aged 
animals while they remain susceptible to obesity-related insulin resistance (Bapat et al., 
2015). This could be explained by the fact that in this model, a loss of VAT-resident Treg cells 
leads to a completely different microenvironment prompting differing reactions. 
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Alternatively, these data could also indicate that the mechanisms of age-related and obesity-
related insulin resistance are distinct. 
1.3.3.2. Ppar-γ signaling and VAT-resident Treg cells 
Ppar-γ has been shown to interact with Foxp3 in VAT-resident Treg cells to induce a 
VAT-specific Treg cell gene signature (Cipolletta et al., 2012; Zhou et al., 2015). A Treg cell 
specific deletion of Ppar-γ had no effect on the Treg cell fraction in lymphoid compartments, 
while it resulted in a distinct decrease of VAT-resident Treg cells to about 10% of the TH-cell 
compartment compared to the 40-60% of VAT-resident Treg cells in control animals. 
Furthermore, these Ppar-γ-deficient VAT-resident Treg cells also exhibited reduced mean 
fluorescence intensity of Foxp3. Moreover, a deletion of Ppar-γ in Treg cells altered the 
expression of VAT-resident Treg cells to more closely resemble that of lymphoid-organ 
resident Treg cells, indicating that Ppar-γ is important for the development and maintenance of 
VAT-resident Treg cells (Cipolletta et al., 2012). Further analysis of these VAT-resident Treg 
cell deficient animals revealed reduced age-induced insulin resistance yet unaltered 
susceptibility to obesity (Bapat et al., 2015), further establishing the vital role that VAT-
resident Treg cells play in the metabolism (Cipolletta et al., 2012). Recent studies have shown 
that this VAT-resident specific Treg cell signature is already established in the spleen and then 
reinforced through signals from the micromilieu in VAT (Li et al., 2018). 
Interestingly, this VAT-resident Treg cell signature is lost in obese mice. However, 
these mice still express a distinct signature from splenic Treg cells, characterized by altered 
expression of several different genes as well as a change in the phosphorylation of PPAR-γ 
(Cipolletta et al., 2015). 
In addition to its direct influence on VAT-resident Treg cell function, Ppar-γ signaling 
also influences the expression of the scavenger receptor CD36 on macrophages, which 
mediates the uptake of low-density lipoproteins, fatty acids, and phospholipids (Tontonoz et 
al., 1998). Treg cell differentiation has been shown to rely selectively on exogenous lipid 
metabolism rather than glucose (Michalek et al., 2011). Thus, the mechanism by which Ppar-γ 
influences the differentiation of VAT-resident Treg cells could also involve altering the lipid 
composition of the microenvironment by affecting CD36 expression on macrophages (Sugii et 
al., 2009; Zhou et al., 2015). 
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1.4. Mesenchyme Homeobox 1 
Mesenchyme Homeobox 1 (MEOX1) is a transcription factor which is required for 
correct gene expression in all somatic compartments (Bayrakli et al., 2013). Transcription 
factors containing Homeobox (HOX) domains have been first described in drosophila and 
have been shown to play an important role in the shaping of animal structures by inducing 
different programs in the early development of both mammals and insects by binding to DNA 
domains through helix-turn-helix structures (Alonso, 2002). 
As such, it is unsurprising that MEOX1 has been shown to be one of the transcription 
factors involved in the epithelial-to-mesenchymal transition (Sun et al., 2016). Mutations 
leading to the loss of MEOX1 mRNA cause Klippel-Feil-Syndrome, a segmentation defect in 
the cervical spine which is characterized by a short neck, limited neck movement, and a low 
hairline (Bayrakli et al., 2013; Mohamed et al., 2013) 
Moreover, MEOX1 has been implicated in breast cancer development as it is located 
in the breast cancer 1 (BRCA1) region, which encodes for several different tumor suppressor 
genes. Mutations in this region highly increase the risk for breast and ovarian cancer (Futreal 
et al., 1994). Furthermore, MEOX1 has been shown to be involved in both the regulation of 
breast cancer stem cells and in mesenchymal-like cell proliferation and increased MEOX1 
expression can be correlated with breast cancer stage, lymph node metastasis and poor 
survival prognosis (Sun et al., 2016). 
However, as of yet, MEOX1 has not been described in the context of T-cell biology or 
immunology. 
1.5. Aim of this thesis 
The immunomodulatory effect of Treg cells is one of the main ways in which the 
immune system self-regulates. However, even though Treg cells were first hypothesized in the 
early 1970s, we still do not completely understand their functionality, especially their 
divergent functions depending on their tissue of residence. 
In this thesis, we attempted to gain a better understanding of Treg cell biology by 
analyzing Treg cells in the VAT, a PGE2-rich environment. We focused especially on the role 
of HPGD, an enzyme which we found to be highly expressed in Treg cells and which is 
important in the metabolism of PGE2. 
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To more closely evaluate the role of HPGD in Treg cell biology, we utilized a Treg cell 
specific Hpgd knockout mouse line generated by crossing two previously published lines 
(Roizen et al., 2008; Rubtsov et al., 2008) and analyzed the effect the loss of Hpgd has on Treg 
cell functionality, on the overall makeup of the immune-cell compartment, as well as on the 
metabolism of these animals. Furthermore, we analyzed the role of HPGD in Treg cells 
isolated from humans suffering from T2D, a very common metabolic disorder, to determine 
whether the metabolic role of HPGD in Treg cells is conserved between the species. 
Finally, we attempted to understand Treg cell signaling upstream of HPGD by studying 
the effect of the transcription factor MEOX1, which we found to be highly upregulated in 
human Treg cells and regulated in a similar manner to HPGD. 
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2. Materials 
2.1. Antibodies 
Table 2: List of murine antibodies for flow cytometry  
Epitope Clone Company Dilution 
B220 RA3-6B2 Biolegend 1:200 
CD11b M1/70 Biolegend 1:200 
CD11c N418 Biolegend 1:400 
CD127 A7R34 Biolegend 1:200 
CD14 Sa14-2 Biolegend 1:200 
CD19 eBio1D3 eBioscience 1:200 
CD25 PC61 Biolegend 1:200 
CD3 17A2 Biolegend 1:200 
CD4 RM4-5 Biolegend 1:200 
CD44 IM7 Biolegend 1:200 
CD45 30-F11 Biolegend 1:200 
CD62L MEL-14 eBioscience 1:200 
CD69 H1.2F3 eBioscience 1:200 
CTLA4 UC10-4B9 eBioscience 1:100 
Eos ESB7C2 eBioscience 1:200 
F4/80 BM8 Biolegend 1:100 
Foxp3 FJK-16s eBioscience 1:100 
GFP polyclonal Invitrogen 1:300 
GITR DTA-1 Biolegend 1:200 
GR-1 RB6-8C5 eBioscience 1:200 
Helios 22F6 eBioscience 1:200 
I-A/I-E M5/114.15.2 Biolegend 1:200 
ICOS 15F9 eBioscience 1:200 
Ki67 SolA15 eBioscience 1:200 
KLRG1 2F1 eBioscience 1:200 
Ly6C HK1.4 Biolegend 1:200 
Ly6G 1A8 eBioscience 1:200 
Neuropilin-1 3E12 Biolegend 1:100 
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NK1.1 PK136 Biolegend 1:200 
NKp46 29A1.4 Biolegend 1:100 
ST2 DIH9 Biolegend 1:100 
 
Table 3: List of human antibodies for flow cytometry 
Epitope Clone Company Dilution 
CD127 HCD127 Biolegend 1:100 
CD25 BC96 Biolegend 1:100 
CD3 UCHT1 Biolegend 1:200 
CD4 RPA-T4 Biolegend 1:200 
Foxp3 PCH101 eBioscience 1:100 
MEOX1 ab23279 Abcam 1:25 
 
Table 4: List of secondary antibodies for flow cytometry 
Epitope Clone Company Dilution 
Goat aRabbit IgG Oligoclonal Invitrogen 1:500 
 
Table 5: List of human antibodies used for bead coating 
Epitope Clone Company 
CD3 OKT3 Janssen-Cilag GmbH 
CD28 9.3 kind gift of James Riley, 
UPenn 
MHCI W6/32 Hybridoma 
 
Table 6: List of western blot primary antibodies 
Epitope Cat. No. Company Dilution 
pAKT (Ser 473) #9271 Cell Signaling  1:1000 
AKT #4685 Cell Signaling 1:500 
MEOX1 ab23279 Abcam 1:1000 
β-Actin MAB1501 Sigma-Aldrich 1:5000 
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Table 7: List of western blot secondary antibodies 
Epitope Cat. No. Company Dilution 
Mouse IRDye800  926-32210 LI-COR Biosciences 1:5000 
Rabbit IRDye680  925-68071 LI-COR Biosciences 1:5000 
Rabbit IgG-HRP  GENA9340 Sigma-Aldrich 1:1000 
Mouse IgG-HRP GENXA931 Sigma-Aldrich 1:1000 
 
Table 8: List of Immunohistochemistry antibodies 
Epitope Clone Cat. No. Company Dilution 
F4/80  CI:A3-1 ab6640 Abcam 1:50 
Rabbit anti-rat IgG, biotin polyclonal 31834 Thermo Fisher Scientific 1:5000 
2.2. Buffers 
Table 9: List of buffer compositions 
Buffer Component 
10x Wet blot Buffer 250 mM Tris Base 
1.92 M glycine 
in H2O 
1x Laemmli Running Buffer 1x 10x Laemmli Running Buffer 
in H2O 
1x Wet Blot Buffer 1x 10x Wet Blot Buffer 
20% (V/V) methanol 
in H2O 
4% PFA solution 4% (w/V) paraformaldehyde 
in PBS, pH adjusted to 6.9 
5x Laemmli Loading Buffer 156.25 mM Tris-HCl, pH 6.8 
5% (w/V) SDS 
54% (V/V) glycerol 
0.0025% (w/V) bromphenol blue 
12.5% β-mercaptoethanol 
in H2O 
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Adipocyte Differentiation Medium 1µM Dexamethasone 
0.5mM Methylisobutylxanthine (IBMX) 
1µg/ml bovine Insulin 
10% FCS 
in DMEM 
Adipocyte Maintenance Medium 1µg/ml bovine Insulin 
10% FCS 
in DMEM 
AT-Digestion Buffer 20 mg/ml BSA 
0.1 mg/ml collagenase type II 
20 µg/ml DNAseI 
in DMEM 
Digestion Buffer 10 mM HEPES 
0.5 mg/ml collagenase type IV 
0.05 mg/ml DNAseI 
in RPMI 
Intestinal Digestion Buffer  0.2U/ml Liberase TM 
200U/ml DNAse 
10mM HEPES 
100U/ml Penicillin  
100µg/ml Streptomycin 
in HBSS 
Intestinal Wash Buffer I 5mM DTT 
2% FCS 
100U/ml Penicillin  
100µg/ml Streptomycin 
in HBSS 
Intestinal Wash Buffer II 5mM EDTA 
2% FCS 
100U/ml Penicillin  
100µg/ml Streptomycin 
in HBSS 
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Intestinal Wash Buffer III 10mM HEPES 
100U/ml Penicillin  
100µg/ml Streptomycin 
in HBSS 
MACS Buffer 0.5% (w/V) BSA 
2 mM EDTA 
in PBS 
MRC Buffer 50 mM Tris-HCl, pH 7.5 
1 mM EGTA, pH 8.0 
1 mM EDTA, pH 8.0 
10 mM β-glycerol phosphate 
50 mM sodium fluoride 
5 mM sodium pyrophosphate 
1 mM sodium vanadate 
270 mM sucrose 
1% (V/V) Triton-X 100 
PBST 0.1% (V/V) Tween-20 
in PBS 
RIPA Buffer 10 mM Tris HCl, pH 8.0 
1 mM EDTA 
140 mM NaCl 
1% (V/V) Triton-X 100 
0.1% (w/V) SDS 
0.1% (w/V) sodium deoxycholate 
in H2O 
Red Blood Cell Lysis (RBCL) Buffer 155 mM ammonium chloride 
10 mM potassium hydrogen carbonate 
0.1 mM EDTA 
0.5% (w/V) SDS 
in H2O 
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2.3. Disposables 
Table 10: List of disposables used 
Kit Manufacturer 
0,2 ml PCR reaction tubes Eppendorf GmbH 
0,5-2,0 ml reaction tubes Eppendorf GmbH 
10 cm plates Sarstedt 
12-well tissue culture plates Sarstedt 
15 ml Falcon tubes Sarstedt 
19 G needle VWR 
24-well tissue culture plates Sarstedt 
48-well tissue culture plates Sarstedt 
50 ml Falcon tubes Sarstedt 
6-well tissue culture plates Sarstedt 
27 G needle VWR 
96 well half-area plate Greiner 
96 well suspension plate Sarstedt 
96-well tissue culture plates Sarstedt 
Cell stainer (100 µm) Greiner 
LightCycler 480 Multiwell Plate and sealing 
foil 
Roche Diagnostics 
MACS C-Tubes Miltenyi Biotec 
MACS LS columns Miltenyi Biotec 
MACS M-Tubes Miltenyi Biotec 
Nitrocellulose-membrane Hybond-C Extra GE healthcare 
Pipette tips (10, 200 & 1,000 µl) Sarstedt 
Pre-Separation Filters Miltenyi Biotech, Bergisch Gladbach (DE) 
Serological pipettes (2, 5, 10 & 25 ml) Sarstedt 
Syringe (2, 5, 10 and 50 ml) Braun 
Z Gel Tubes Sarstedt 
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2.4. Enzymes 
Table 11: List of enzymes used 
Enzyme Supplier 
Collagenase Type II Sigma Aldrich 
Collagenase Type IV Sigma Aldrich 
DNAseI Sigma Aldrich 
Liberase TM Roche Diagnostics 
MyTaq™ HS DNA Polymerase Bioline 
2.5. Equipment 
Table 12: List of equipment used 
Equipment Manufacturer 
AccuChek Avia Roche Diagnostics 
Analysis Scale MS104S Mettler Toledo 
Centrifuge 5810R Eppendorf GmbH 
Centrifuge 5815R Eppendorf GmbH 
Centrifuge AvantiTM J-20 XP Beckman Coulter 
Centrifuge Mikro-200R Hettich 
Centrifuge Rotina 420R Hettich 
CO2 Incubator Heraeus Christ Instruments 
Dynal magnet MPC-S Dynal Biotech 
Electroporator Amaxa 
Flow cytometer / cell sorter FACS Aria III BD Biosciences 
Flow cytometer FACS CANTO BD Biosciences 
Flow cytometer FACS LSR II BD Biosciences 
Gene pulser XCell BioRad Laboratories 
GentleMACS dissociator Miltenyi Biotec 
Magnet MACS Multi Stand Miltenyi Biotec 
Microplate reader Infinite M200 Tecan Austria GmbH 
Mini-& MidiMACS Separation Units Miltenyi Biotec 
Mini-Protean Electrophoresis System Bio-Rad Laboratories 
Multi-Detection Microplate Reader Synergy 
HT 
BioTek Instruments 
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Odyssey Infrared Imaging System LI-COR Biosciences 
Pharmacia Pump P-1 Pharmacia 
pH-meter S20-SevenEasy Mettler Toledo 
Pipette Controller Accu Jet Plus Brand GmbH 
Pipette Multipette Plus Eppendorf GmbH 
Pipette Set Ergo One Starlab 
PowerPac HC Power Supply Bio-Rad Laboratories 
Real-time PCR system LightCycler 480 Roche Diagnostics 
Roller Mixer SRT9D Stuart Bibby Scientific 
Scale EL2001 Mettler Toledo 
Shaking incubator Stuart 
Spectrophotometer NanoDrop 2000 Thermo Scientific 
Steril work bench BDK 
Vortexer Velp Scientifica 
Water bath Memmert 
2.6. Kits 
Table 13: List of kits used 
Kit Manufacturer 
12-230 kDa Wes Separation Module kit Protein Simple 
CD4 M-pluriBeads Kit PluriSelect 
CD4+ T cell isolation kit II, mouse Miltenyi Biotech 
Transcription factor staining buffer set eBioscience 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 
Prostaglandin E Metabolite EIA Kit Cayman Chemicals 
Transcriptor 1st Strand cDNA Synthesis Kit Roche 
Ultrasensitive Mouse Insulin ELISA Mercodia 
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2.7. Mouse Lines 
Table 14: List of mouse lines used 
Mouse Line Reference 
CD4-Cre Lee et al., 2001 
Foxp3-YFP-Cre Rubtsov et al., 2008 
Hpgd flox Roizen et al., 2008 
Ppar-γ flox Akiyama et al., 2002 
2.8. Cell Lines 
Table 15: List of cell lines used 
Cell Line Reference 
HEK293T ATCC CRL-11268 
3T3-L1 ATCC CL-173 
2.9. Oligonucleotides 
Table 16: List of murine qRT-PCR primer sequences 
Target Sequence Probe 
β-Actin forward: 5’-CTA AGG CCA ACC GTG AAA AG-3’ 
reverse:  5’-ACC AGA GGC ATA CAG GGA CA-3’ 
#64 
Ap2 forward: 5’-GGA TGG AAA GTC GAC CAC AA-3’ 
reverse:  5’-TGG AAG TCA CGC CTT TCA TA-3’ 
#31 
Angptl4 forward: 5’-GGG ACC TTA ACT GTG CCA AG-3’ 
reverse:  5’-GAA TGG CTA CAG GTA CCA AAC C-3’ 
#83 
Foxp3 forward: 5’-ACC ACA CTT CAT GCA TCA GC-3’ 
reverse: 5’-CCA GTG GCA GCA GAA GGT-3’ 
#75 
Hpgd forward: 5’-TCA GAA GAC ACT GTT CGT CCA-3’ 
reverse:  5’-TCC AAT CTT CCG AAA TGG TC-3’ 
#46 
Ppar-γ forward: 5’-TTA TAG CTG TCA TTA TTC TCA GT-3’ 
reverse:  5’-GAC TCT GGG TGA TTC AGC TTG-3’ 
#62 
Ptgr1 forward: 5’-GAC TGA GCT CCC ACC CTT AAA-3’ 
reverse:  5’-GAC TGA GCT CCC ACC CTT AAA-3’ 
#18 
Ptgr2 forward: 5’-GGA GGT GAC ATC AGC AAC G-3’ 
reverse:  5’-CTG AGA AAT CTG ACC ACA CAG G-3’ 
#5 
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Insr1 forward: 5’-CGG TAG CCT GAT CAT CAA CAT-3’ 
reverse:  5’-TCT TCA ATG AGG CCA AGG TTA-3’ 
#78 
Irs1 forward: 5’- CTA TGC CAG CAT CAG CTT CC-3’ 
reverse:  5’- TTG CTG AGG TCA TTT AGG TCT TC-3’ 
#71 
Irs2 forward: 5’- TCC AGG CAC TGG AGC TTT-3’ 
reverse:  5’-GGC TGG TAG CGC TTC ACT-3’ 
#53 
 
Table 17: List of human qRT-PCR primer sequences 
Target Sequence Probe 
B2M forward: 5’-TTC TGG CCT GGA GGC TAT-3’ 
reverse:  5’-TCA GGA AAT TTG ACT TTC CAT TC-3’ 
#42 
FOXP3 forward: 5’-ACC TAC GCC ACG CTC ATC-3’ 
reverse:  5’-TCA TTG AGT GTC CGC TGC T-3’ 
#50 
HPGD forward: 5’- GGT TCC ACT GAT AAC AGA AAC CA-3’ 
reverse:  5’-TTT GGT CAA TAA TGC TGG AGT G-3’ 
#48 
MEOX1 forward: 5’-GAC TGC AAA AGG GGA CAA GA-3’ 
reverse:  5’-CAG CAA GAG CTT AAA TCC ATC C-3’ 
#69 
PTGR1 forward: 5’-GCA GCC AAA AGA TTG AAG GA-3’ 
reverse:  5’-GGC TAC ATT TTT ACT TTC CAC AAC T-3’ 
#43 
PTGR2 forward: 5’-CGG TAA TAA ATG GGT TGG AAA A-3’ 
reverse:  5’-CTG CTT TCC AAT GTT ACC TCC T-3’ 
#24 
 
Table 18: List of siRNA sequences 
Target Sequence 
FOXP3 sense: 
antisense: 
5’-GCA CAU UCC CAG AGU UCC-3’ 
5’-AGG AAC UCU GGG AAU GUG C-3’ 
MEOX1 sense: 
antisense: 
5’-CAC UGC CAA UGA GAC AGA GAA GAA A-3’ 
5’-UUU CUU CUC UGU CUC AUU GGC AGU G-3’ 
Scrambled sense: 
antisense: 
5’-UUC UCC GAA CGU GUC ACG U-3’ 
5’-ACG UGA CAC GUU CGG AGA A-3’ 
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Table 19: List of primers for Hpgd genotyping 
Primer Sequence 
sense: 5’-TCT TTA GTC TGA ACC AAT CC-3’ 
antisense 1: 5’-AGA AGA AGA CAG GCA AAT AA-3’ 
antisense 2: 5’-GCA TGA CTG TCA TTG AAA CT-3’ 
2.10. Reagents 
Table 20: List of reagents and suppliers 
Reagent Supplier 
10% SDS Applichem 
15-keto-PGE2 Cayman Chemical 
30 % Acrylamide/bis Solution 29:1 Bio-Rad Laboratories 
480 Probe Master Roche Diagnostics 
6x Purple Loading Dye Fermentas GmbH 
Agarose Applichem 
Ammonium persulfate (APS) Sigma-Aldrich 
Ammoniumacetate Merck 
BD Pharm Lyse Buffer  BD Biosciences 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenole blue Roth 
CD14+ Microbeads BD Biosciences 
CD25+ Microbeads II BD Biosciences 
Cell Proliferation Dye eFluor 670 eBioscience 
CFSE Sigma-Aldrich 
Chloroform Applichem 
Complete mini Protease Inhibitor cocktail tablets Roche Diagnostics 
CountBright Absolute Counting Beads Invitrogen Life Technologies 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DSS Sigma Aldrich 
Dulbecco’s Modified Eagle Medium (D-MEM) PAA Laboratories GmbH  
Dynabeads M-450 Tosylactivated Thermo Fisher Scientific 
ECL Western Blotting Substrate Promega 
EDTA Sigma-Aldrich 
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EGTA Sigma-Aldrich 
Ethanol Roth 
Fc receptor blocking reagent, human Miltenyi Biotec 
Fc receptor blocking reagent, murine Biolegend 
Fetal calf serum (FCS) Sigma-Aldrich 
Forane (Isolfourane) Baxter 
Formaldehyde solution (37 %) Sigma-Aldrich 
Gibco distilled water (RNase/ DNase free) Invitrogen Life Technologies 
Glucose Merck 
Glutamax (100 x) Invitrogen Life Technologies 
Glycerol (87 %) Applichem 
Glycine  Sigma Aldrich 
GM-CSF ImmunoTools 
HEPES Applichem 
IL-2 ImmunoTools 
IL-4 ImmunoTools 
Insuman Rapid (40 I.E./ml) Sanofi 
Isopropanol Applichem 
Laemmli buffer for SDS-PAGE (10x) Serva 
Methanol Roth 
Near-IR fixable live dead stain Invitrogen Life Technologies 
O’GeneRuler 1 kb Plus DNA-Ladder Fermentas GmbH 
O’GeneRuler 50bp DNA-Ladder Fermentas GmbH 
Odyssey Two-Color Molecular Weight Marker Licor Biosciences 
Pancoll human (density 1.077 g/L) PAN Biotech GmbH 
Paraformaldehyde Sigma-Aldrich 
Penicillin/Streptomycin Gibco 
PGD2 Cayman Chemical 
PGE2 Sigma-Aldrich 
PGF2a Cayman Chemical 
PGJ2 Cayman Chemical 
Phosphate buffered saline (PBS) PAA Laboratories GmbH 
PhosStop (Phosphatase Inhibitor) Roche Diagnostics 
Materials 
 
31 
 
Propidium iodide (PI) Sigma-Aldrich 
Qiazol (Trizol) Qiagen 
Re-Blot plus mild solution (Chemicon) Merck 
rmGM-CSF Peprotech 
rmIL4 Peprotech 
rmM-CSF Peprotech 
RPMI cell culture medium (1640) Pan Biotec 
SeeBlue Plus 2 standard Thermo Fisher Scientific 
siRNA-buffer  Dharmacon  
Skim Milk powder Roth 
Sodium dodecylsulfate (SDS) powder Roth 
Sodium fluoride Sigma-Aldrich 
Sodium hydroxide (NaOH) Merck 
Sodium pyrophosphate Sigma-Aldrich 
Sodium vanadate Sigma-Aldrich 
SYBR Green Master Mix Fermentas  
TEMED Applichem 
Tris Applichem 
Tris-HCl Applichem 
Triton X-100 Applichem 
Turbofect in vitro Transfection Reagent Fermentas GmbH 
Tween 20 Applichem 
X-vivo 15 cell culture medium Lonza 
β-Glycerol Phosphate Sigma-Aldrich 
β-Mercaptoethanol Applichem 
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2.11. Software 
Table 21: List of software used 
Software Developer 
Compass for Simple Western, Version 3.0 Protein Simple 
CorelDRAW, Version 19.1.0.419 Corel Corporation 
Flow Jo, Version 10.4.2 FlowJo, LLC 
GraphPad Prism 7.02 Graph Pad Software, Inc 
Image J Fiji, Version 1.51s Schindelin et al., 2012 
LightCycler 480 Software, Version 1.5.0.39 Idaho Technology, Inc 
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3. Methods 
3.1. Isolation of murine cells and serum 
Prior to cell isolation, mice were anesthetized by isoflourane inhalation and sacrificed 
by cervical dislocation unless perfusion was required, in which case mice were anesthetized 
with 100 mg/kg bodyweight ketamine and 10 mg/kg bodyweight xylazine and perfused with 
20 ml PBS through the left ventricle under animal license AZ 84-02.04.2016.A284. 
3.1.1. Isolation of cells from bone marrow  
Mice were sacrificed by cervical dislocation and the femurs and tibias were excised. 
Bone marrow (BM) was flushed out of the bones with MACS buffer and collected in a 
reaction tube. Cells were centrifuged at 400 g for 5 min at 4° C and resuspended in 1 ml of 
RBCL buffer. Cells were incubated for 2 min at room temperature (RT) while shaking gently. 
The lysis was stopped with 5 ml PBS and repeated if necessary. Cells were washed twice in 
PBS by centrifuging at 400 g for 5 min at 4°C, removing the supernatant and repeating the 
centrifugation step. After washing, the supernatant was removed and cells were used for 
subsequent experiments. 
3.1.2. Isolation of cells and serum from blood 
Mice were euthanized by inhalation of an isofluorane overdose and blood was drawn 
directly from the heart by cardiac puncture. For cell isolation, blood was transferred to a 
reaction tube and RBCL was performed as with cells isolated from the BM (see section 3.1.1). 
Cells were washed and resuspended in PBS for subsequent staining. For serum isolation, 
blood was and transferred into Z-Gel tubes containing a gel with clotting factors. After 5 min 
of incubation at RT, tubes were centrifuged at maximum speed for 5 min and the serum was 
transferred into a new tube and stored at -80°C until use. 
3.1.3. Isolation of cells from the kidney 
Mice were perfused, the kidneys were excised and their capsule was removed with the 
help of a forceps. The kidneys were subsequently homogenized and digested in 3 ml digestion 
buffer at 37°C for 45 min. The reaction was stopped with 5 ml PBS and the homogenate was 
resuspended and filtered through a 100 µm mesh. The homogenate was then layered onto 5 ml 
pancoll and centrifuged at 700 g for 20 min with the brake disengaged. The interphase 
containing the cells was collected and washed with PBS by centrifuging at 500 g for 7 min 
before resuspending in PBS for staining. 
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3.1.4. Isolation of cells from the lung 
Mice were perfused and the lung was excised and homogenized through a 100 µm 
mesh. The homogenate was then layered onto a pancoll gradient and cells were collected as in 
3.1.3. Washed cells were resuspended in PBS for staining. 
3.1.5. Isolation of cells from LNs 
Mice were sacrificed by cervical dislocation and LN were excised and homogenized 
through a 100 µm mesh. Cells were washed once with 10 ml PBS and centrifuged at 400 g for 
5 min at 4°C and resuspended in PBS for staining. 
3.1.6. Isolation of cells from the spleen 
Mice were sacrificed by cervical dislocation and the spleen was excised and 
homogenized through a 100 µm mesh. If splenic myeloid cells were analyzed, the tissue was 
resuspended in 3 ml digestion buffer and digested at 37°C for 45 min before RBCL. The 
digestion was omitted if only T cells were analyzed by flow cytometry. RBCL was performed 
as described for the BM (see section 3.1.1). Cells were washed and then resuspended in PBS 
for subsequent staining or sorting. 
3.1.7. Isolation of cells from adipose tissue 
Mice were perfused and adipose tissue was excised. If adipose tissue was isolated in 
order to stain for ST2, the tissue was cut into small pieces and transferred into 10 ml of AT-
digestion buffer and incubated for 45 min at 37°C. The reaction was then stopped with 40 µl 
0.5M EDTA and incubated at RT for 2 min before transferring the homogenate through a 100 
µm mesh into a new reaction tube. Cells were centrifuged at 400 g for 5 min and washed once 
with PBS before resuspending in PBS for ST2 staining. 
If cells were isolated for other stainings, adipose tissue was transferred into 
GentleMACS C Tubes with 3 ml of digestion buffer and homogenized on the GenlteMACS 
dissociator using the ‘m_brain_1’ program. After incubating at 37°C for 15 min, the sample 
was dissociated again, this time using the ‘m_brain_2’ program followed by another 15 min 
of incubation at 37°C. After the last incubation step, cells were transferred through a 100 µm 
mesh, centrifuged at 400 g for 5 min and washed with PBS before staining for flow cytometry 
or sorting. 
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3.1.8. Isolation of cells from the colon 
The colons were removed from animals and associated patches of adipose tissue 
removed before flushing the intestinal content and cutting the colon into small pieces. To 
remove the mucosal layer, colon pieces were incubated in intestinal wash buffer I for 20 min 
at 37° C at 200 rpm. Epithelial cells were removed by washing the tissue in intestinal wash 
buffer II three times for 15 min each at 37°C at 200 rpm. EDTA and FCS were removed by 
washing in intestinal wash buffer III for 10 min at 37°C, 200 rpm. The tissue was then 
digested in intestinal digestion buffer for 45 min at 37°C, 200 rpm after which the reaction 
was stopped with MACS buffer. Cells were filtered through a 70 µm mesh and washed twice 
with HBSS containing 2% FCS before staining for flow cytometry. 
3.1.9. Isolation of cells from the skin 
To isolate cells from the skin, a 2cm
2
 area of the skin from the trunk of the animals 
was depilated, excised and lightly defatted. The tissue was minced and digested in PBS 
containing 0.8 U/mL Liberase and 200U/mL DNAse I at 37°C, 150 rpm for 90 min. A single 
cell suspension was then generated by pipetting up and down and filtering cells through a 
70 µm cell mesh before proceeding to FACS staining. 
3.2. Isolation of cells from human peripheral blood 
All experiments conducted with human samples were performed in compliance with 
the institutional review boards and covered by Reg. No. 017-12-23012012 (T2D patient blood 
samples) or 288/13 (isolation of cells from buffy coats). All donors provided written and 
informed consent. 
For experiments with cells from healthy individuals or T2D patients depicted in Figure 
40, cells were isolated from whole blood while all other experiments were conducted with 
cells isolated from buffy coats. For analysis of T-cell populations, samples were enriched for 
CD4
+
 T cells using CD4
+
 pluribeads according to manufacturer’s instructions. Samples were 
then either stained with antibodies and sorted using the BD FACS ARIA III or further purified 
using human CD25 microbeads according to manufacturer’s instructions. Both the CD25+ 
fraction, containing the Treg cells, and the CD25
-
 fraction, containing the Tconv cells, were 
collected for subsequent analysis. 
Methods 
 
36 
 
3.3. Antibody staining for flow cytometry 
3.3.1. Extracellular staining 
After cell isolation, cells were stained with antibodies binding to cell-surface proteins. 
Thus, cells were transferred into a 96-well plate and resuspended in PBS to a final reaction 
volume of 50 µl. A master mix containing FC receptor block, fluorochrome-coupled 
antibodies and, if required, near-IR fixable live-dead stain was prepared and added to the 
reaction to yield final dilutions of 1:300 for the FC receptor block, between 1:50 and 1:400 for 
the antibodies and 1:1,000 for the live-dead stain. Cells were then incubated at 4°C for 20 min 
in the dark. Cells were washed with PBS and centrifuged at 400 g for 5 min. The supernatant 
was decanted and cells were resuspended in 200 µl PBS prior to acquiring them on a flow 
cytometer. If cells were not immediately acquired, they were stored at 4°C in the dark. If cells 
were stored for longer than a few hours, cells were fixed as described in section 3.3.3. 
3.3.2. Sorting of human and murine T cells 
Cells were stained as described in section 3.3.1. Human cells were stained for CD3, 
CD4, CD25 and CD127. The following populations were isolated using a BD FACS Aria III 
sorter: CD3
+
CD4
+
CD25
+
CD127
-
 Treg cells and CD3
+
CD4
+
CD25
-
CD127
+
 Tconv cells. Murine 
cells expressing YFP under the control of the Foxp3 promoter were stained for CD45, CD3, 
CD4 and CD25, as described in section 3.3.1. Treg cells, defined as CD45
+
CD3
+
CD4
+
CD25
+
 
and YFP
+
, and Tconv cells, defined as CD45
+
CD3
+
CD4
+
CD25
-
 and YFP
-
, were sorted. To sort 
for naïve T cells, cells were additionally stained for CD44 and CD62L. Naïve T cells were 
defined as CD45
+
CD3
+
CD4
+
CD25
-
YFP
-
CD44
-
CD62L
+
 and sorted using a BD FACS Aria III 
cell sorter. 
Murine cells sorted from the spleen were pre-enriched using the CD4
+
 T cell isolation 
kit II according to manufacturer’s instructions. Cells isolated from either the VAT or the 
kidney were pre-enriched by sorting for CD45
+
 cells prior to sorting for Treg or Tconv cell 
populations. 
3.3.3. Intracellular YFP staining 
After extracellular staining, cells were centrifuged at 400 g for 5 min at 4°C and then 
fixed in 200 µl 4% PFA buffer for 10 min on ice in the dark. Following the fixation step, cells 
were centrifuged at 700 g for 2 min at 4°C and washed twice in 1x Permeabilization Buffer. 
Cells were then counterstained with a flourochrome coupled anti-GFP antibody, which is 
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cross-reactive for YFP, at a final concentration of 1:300 at RT for 30 min. After washing once 
with 1 x Permeabilization Buffer, cells were fixed and stained for intracellular transcription 
factors as described in section 3.3.4. 
3.3.4. Intracellular transcription factor staining 
Intracellular transcription factor staining of cells was performed using the transcription 
factor staining buffer set in a 96-well plate according to the manufacturer’s instructions. 
3.3.5. MEOX1 staining 
MEOX1 staining was performed using the intracellular transcription factor staining 
buffer set as described in section 3.3.4. After washing once with 1x Permeabilization Buffer, 
cells were stained with a fluorochrome-coupled goat anti-rabbit secondary antibody for 1hr at 
room temperature. Subsequently, cells were washed once with 1X Permeabilization Buffer 
and once in PBS. 
3.3.6. CD1d Tetramer staining 
CD1d staining was performed using tetramers loaded by the NIH tetramer core 
facility. Cells were resuspended in 200µl of PBS and stained with either empty tetramer or 
CD1d loaded, fluorescently labeled tetramers in a dilution of 1:400 for 15 min at RT. Cells 
were then washed in PBS and resuspended in PBS prior to acquiring on a flow cytometer. 
3.3.7. FOXP3 staining of T2D samples 
For FOXP3 staining of T2D patient samples and healthy control samples, 1ml of 
peripheral blood was used per staining and surface antibodies were added to whole blood 
samples in adequate dilutions. Subsequently, red blood cells were lysed using the BD Pharm 
Lyse Buffer according to the manufacturer’s instructions. If necessary, lysis was repeated. 
Subsequently, cells were fixed, permeabilized and stained as described in section 3.3.4. 
3.3.8. Quantification of cell numbers by flow cytometry 
To quantify cells, CountBright counting beads were added to the cells prior to 
antibody staining. Absolute cell numbers could be calculated based on the following formula: 
absolute cell number =  
cells aquired by flow cytometer x total beads added to reaction
beads aquired by flow cytometer
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3.4. ELISAs 
3.4.1. Metabolite assay 
To determine the ability of human Treg and Tconv cells to metabolize PGE2, human Treg 
and Tconv cells were isolated as described in section 3.2. Cells were then stimulated with 100 
U/ml of IL-2 and 1 µM PGE2 for 24 hours before assessing the amount of PGE2 metabolite in 
the cell supernatant with the Prostaglandin E Metabolite EIA Kit according to the 
manufacturer’s instructions. 
3.4.2. Insulin ELISA 
Animals were fasted overnight and blood was drawn. Serum was collected as 
described in section 3.1.2. Insulin levels were determined with the Ultrasensitive Mouse 
Insulin ELISA performed in 96-well half-area plates according to manufacturer’s 
specifications. 
3.5. Cell culture 
Cells were cultured in an incubator at 37°C with 5% CO2. Human primary T cells 
were cultured in X-Vivo 15 medium supplemented with 10% FCS and 1% Glutamax. In 
contrast, murine T cells were cultured in IMDM supplemented with 10% FCS, 1% Glutamax, 
55 µM β-Mercaptoethanol, 0.5 mM Sodiumpyruvate, 1% Non-essential amino-acids and 5 
mM HEPES. Meanwhile, HEK293T and 3T3-L1 cells were cultured in DMEM supplemented 
with 10% FCS, 1% Glutamax and 1% Penicilin/Streptomycin. Both cell lines were allowed to 
grow to a confluency of approximately 70% before passaging. 
3.5.1. Suppression assays 
To analyze the suppressive capability of Treg cells, human and murine Treg and Tconv 
cells were isolated as described in section 3.3.2. Human Tconv cells were then stained with 
CFSE at a final concentration of 5.5 mM for 8 min in the dark at RT. The staining was 
stopped with FCS and the cells were washed twice with full medium. Murine Tconv cells were 
stained with eFlour670 according to manufacturer’s specifications. 
Tconv cells were then co-cultured with Treg cells in different ratios and either 
CD3/CD28/MHC-I coated beads for human or Mouse T-Activator CD3/CD28 Dynabeads for 
T-Cell Expansion and Activation for murine cells, respectively, were added at a ratio of 1 
bead for every 3 cells. Cells were then cultivated in the presence or absence of different 
prostaglandins for 3 days before measuring the proliferation on a flow cytometer by 
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determining proliferation-dependent CFSE dilution as a measure of the rate of Tconv 
proliferation where a higher dilution is indicative of more proliferation. 
3.5.2. Transfection of HEK293T cells 
To transfect cells, 2.5x10
5
 HEK293T cells were seeded in 6-well plates and cultivated 
overnight to reach a confluency of approximately 70 – 80%. The transfection was carried out 
using the Turbofect in vitro Transfection Reagent according to the manufacturer’s 
specifications. 
Transfection efficiency was assessed by analyzing GFP expression by flow cytometry 
after 24 hours. Cells were analyzed for gene expression by qRT-PCR as described in section 
3.7 after 48 hours. 
3.5.3. siRNA knockdown 
3.5.3.1. Preparation of siRNA 
Single-stranded siRNA was dissolved to a final concentration of 500 µM in sterile 
H2O and annealed by combining 30 µl of both the sense and antisense siRNA together with 
15 µl 5x siRNA-buffer. The mixture was then heated to 90°C for 1 minute and subsequently 
cooled down to RT over the span of an hour. Afterwards, the mixture was heated to 90°C 
again and then incubated at 37°C for 1 hour. The annealed oligos were stored at -80°C until 
use. 
3.5.3.2. Transfection of siRNA into primary human T cells 
To perform a knockdown of the target gene, siRNA specific for the gene of interest 
was introduced into primary Treg or Tconv cells, isolated as described in section 3.2. As a 
control, scrambled siRNA was transfected instead of the specific siRNA.  
Briefly, 5x10
6
 cells were resuspended in 100 µl human T cell nucleofector solution 
with 5 µl of the annealed siRNA in an electroporation cuvette. The cells were then transfected 
using the U14 program on an AMAXA electroporator. Subsequently, cells were transferred 
into a 24-well plate with prewarmed X-Vivo 15 medium, supplemented with 10% FCS and 
1% Glutamax. After 48 hours, RNA was isolated and gene expression was analyzed by qRT-
PCR as described in section 3.7. 
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3.5.4. IL-2 time kinetics of human primary Treg cells 
Human primary CD4
+
CD25
+
 Treg cells were isolated as described in section 3.2. Cells 
were seeded onto 96-well plates at a final concentration of 2x10
5
 cells/well and stimulated 
with either 0, 10, 100 or 1,000 U/ml of IL-2. Cells were harvested after 0, 12, 24, 48 and 72 
hours with Trizol, RNA was isolated and gene expression was analyzed by qRT-PCR as 
described in section 3.7. 
3.5.5. Differentiation of human monocytes 
To differentiate human monocytes into macrophages or dendritic cells, blood from 
human buffy coats was layered over pancoll and centrifuged at 900 g for 25 min without a 
brake and the PBMCs located at the interphase were collected. Monocytes were then isolated 
from the PBMC population by using human CD14 MACS beads according to the 
manufacturer’s instructions. Cells were subsequently differentiated into macrophages or 
dendritic cells as previously published using a cocktail of 500U/ml GM-CSF for macrophage 
differentiation or 800 U/ml GM-CSF and 500 U/ml IL-4 for dendritic cell differentiation for 6 
days with a medium change after three days (Xue et al., 2014). 
3.5.6. Differentiation and stimulation of 3T3-L1 cells into adipocytes 
Prior to differentiation, cells were allowed to reach 100% confluency for 48 hours. 
Cells were then stimulated with adipocyte differentiation medium for 48 hours. After 48 
hours, adipocyte differentiation medium was exchanged for adipocyte maintenance medium 
and cells were allowed to further differentiate for another 6 days before stimulating cells with 
either 1 µM 15-keto-PGE2, 1 µM Rosiglitazone or DMSO as vehicle control. Cells were then 
harvested and lyzed in Trizol for subsequent qPCR analysis (see section 3.7). 
3.5.7. Differentiation and stimulation of bone-marrow derived macrophages 
(BMDMs) and dendritic cells (BMDCs) 
Isolation of cells from the BM was performed as described above (see chapter 3.1.1). 
For differentiation into BMDMs, cells were then differentiated for 6 days in DMEM 
containing 10% FCS and 20 ng/ml rmM-CSF. Cells were then stimulated with 1 µM 15-keto-
PGE2, 1 µM Rosiglitazone or DMSO as vehicle control overnight before harvesting and lysis 
in Trizol for qPCR analysis (see section 3.7). 
To analyze the effect of 15-keto-PGE2 and Rosiglitazone on the differentiation of 
BMDCs, cells were stimulated with 20 ng/ml rmGM-CSF and 2 ng/ml IL-4 in DMEM 
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containing 10% FCS. After 3 days, 1 µM 15-keto-PGE2, 1 µM Rosiglitazone or DMSO as 
vehicle control was added to the differentiation. After another 3 days, cells were stained with 
antibodies for flow cytometric analysis as described above (see section 3.3.1). 
3.6. In vivo assays 
Mice used for experiments were housed under specific pathogen-free conditions. All 
experiments conducted followed the principles of laboratory animal care as elucidated by the 
NIH (NIH, 2011). All experiments were approved by the Animal Care Commission of North 
Rhine-Westphalia. Mice were used between 6 and 10 weeks of age, unless denoted as aged 
animals in which case they were defined as more than 40 weeks old. All mice, unless 
otherwise specified, were male. 
3.6.1. DSS colitis 
The induction of DSS colitis in animals was approved by the commission for animal 
care under the animal license AZ 84-02.04.2011.A167. Colitis was induced by replacing the 
drinking water of the animals with a 5% (w/v) DSS solution in distilled water. Female 
animals with Hpgd competent or deficient Treg cells were given ad libitum access to the DSS 
solution for 6 days and scored and weighed daily to track disease progression. 
Animals were sacrificed after 6 days and 10 µl serum and 10 mg colon were harvested 
and used for MS at the Institute of Clinical Pharmacology in Frankfurt by the group of N. 
Ferreirós to analyze PGE2 levels as previously described (Lacroix et al., 2015; Schmitz et al., 
2014). 
3.6.2. Adoptive transfer colitis 
Adoptive transfer experiments were conducted as approved by the relevant authorities 
under AZ 84-02.04.2013.A248. Cells were isolated from the spleen of animals with either 
Hpgd-deficient or competent Treg cells and naïve T cells or Treg cells were isolated as 
described in section 3.3.2. 
Colitis was induced by intravenously injecting either 1x10
6
 naïve T cells or 1x10
6
 
naïve T cells and 2.5x10
5
 either Hpgd-competent or deficient Treg cells into Rag2
-/-
 animals. 
Animals were weighed and scored three times a week for six weeks until they were sacrificed 
for analysis. 
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Flow cytometric analysis was performed on LNs and spleen as described above (see 
sections 3.1.5, 3.1.6 and 3.3). 
For histological analysis and scoring, the colon was excised, cleaned, and stored in 4% 
PFA solution. Colons were then embedded in paraffin and stained with hematoxylin and eosin 
and disease severity was scored by the group of C. Wickenhauser at the University Hospital 
of Halle, Institute of Pathology as described previously (Beyer et al., 2011). 
3.6.3. Adoptive transfer experiments 
Adoptive transfer experiments were conducted in the same manner as adoptive transfer 
colitis. However, in addition to injecting 1x10
6
 naïve T cells and 2.5x10
5
 Hpgd-competent or 
Hpgd-deficient Treg cells into Rag2
-/-
 animals, 2.5x10
5 
Hpgd-competent RFP
+
 Treg cells were 
co-transferred to avoid the development of colitis. Recipient mice were weighed and scored 
three times a week and sacrificed after 6 weeks. Flow cytometric analysis was performed as 
described in section 3.6.2 and Treg cells were sorted from mLN for subsequent transcriptomic 
analysis (see section 3.7.5). 
3.6.4. High fat diet experiments 
High fat diet experiments were conducted according to animal license AZ 84-
02.04.2016.A282. Animals were put on a low caloric diet for 2 weeks at 3 weeks of age, after 
which they either continued to be fed the low caloric diet or were switched to a high caloric 
diet for the next 15 weeks. Animals were weighed and scored once a week for the duration of 
the experiment. Glucose and insulin tolerance were tested as described in section 3.6.5. 
3.6.5. Insulin and glucose tolerance tests 
Animals were tested for their tolerance towards insulin and glucose as approved by the 
committee for animal care in the license AZ 84-02.04.2016.A282. Animals were fasted either 
overnight or for 4 hours to analyze glucose or insulin tolerance, respectively. Animals were 
then weighed and their fasting glucose levels were determined by drawing one drop of blood 
from the tail vein and measuring glucose content with an Accu-Chek Aviva. Either 2 g 
glucose/kg bodyweight or 1 U insulin/kg bodyweight were injected intraperitoneally and 
glucose levels were measured 20, 40, 60, 80, 120, and 240 min post injection to test glucose 
tolerance or 15, 30, 60, 120, and 240 min post injection for insulin tolerance. 
Methods 
 
43 
 
3.6.5.1. Calculating the Homeostatic Model Assessment for Insulin Resistance  
To determine the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), 
the fasting glucose and insulin were determined after an overnight fasting period as described. 
The following formula was used to calculate the HOMA-IR: 
HOMA − IR =  
fasting glucose (
mg
ml ) ∙ fasting insulin (
mg
ml )
405
 
3.7. RNA isolation, cDNA synthesis, qRT-PCR and SmartSeq2 
3.7.1. RNA isolation 
Protocols for RNA isolation differ depending on whether RNA was extracted from 
whole tissues, from cell suspensions containing fewer than 10,000 cells or from cell 
suspensions containing more than 10,000 cells. 
When isolating RNA from whole tissue samples, samples were harvested from 
animals and flash frozen in liquid nitrogen. Prior to RNA extraction, tissue was transferred 
into gentleMACS M Tubes with 500 µl Trizol and dissociated on a gentleMACS dissociator 
using the program ‘m_protein_1’. Subsequently, samples were incubated at RT for at least 5 
min to allow for complete dissociation. After dissociation, 200 µl chloroform was added per 
ml of trizol and vortexed. The mixture was incubated at RT for 3 min before centrifuging at 
4°C for 10 min at 12,000 g. The aqueous phase was collected and transferred into a new 
reaction tube containing 400 µl isopropanol and the RNA was precipitated at -20°C for 2 
hours. After precipitation, samples were centrifuged at 12,000 g for 30 min at 4°C and the 
supernatant was decanted followed by two washing steps with 800 µl of 80% Ethanol. After 
washing, pellets were air-dried for approximately 20 min and solved in 20 µl RNAse and 
DNAse free water. RNA concentrations were determined using a spectrophotometer. 
Cell suspensions containing more than 10,000 cells were resuspended in 500 µl Trizol 
and incubated at RT for 5 min. RNA isolation was performed following the same protocol as 
for the isolation of RNA from whole tissue samples. 
If fewer than 10,000 cells were isolated, RNA was extracted using the RNeasy Micro 
Kit according to the manufacturer’s instructions.  
Methods 
 
44 
 
3.7.2. cDNA synthesis 
Isolated RNA was converted into cDNA using the Transcriptor First Strand cDNA 
Synthesis Kit. Ideally, at least 200 ng of RNA was used for the conversion reaction, however 
as little as 50 ng input material can yield cDNA with adequate quality for qRT-PCR.  
 The RNA was adjusted to a final volume of 12 µl and 50 pmol oligo(dT) primer was added 
yielding a final volume of 13 µl. Denaturing and oligo annealing was performed at 65°C for 
15 min. For the reverse transcription reaction 0.5 µl RNAse Inhibitor, 2 µl 10mM dNTPs, 0.5 
µl reverse transcriptase and 4 µl of 5 x reaction buffer were added, yielding a final volume of 
20 µl. Reverse transcription was carried out at 55°C for 30 min followed by heat inactivation 
at 85°C for 5 min. 
3.7.3. qRT-PCR reaction 
Prior to setting up the qRT-PCR reaction, cDNA was diluted to a final volume of 100 
µl. qRT-PCR reactions were either carried out using the Roche 480 Probe master system 
(reaction set-up Table 22, qRT-PCR program Table 23) or the SYBR green system (reaction 
set-up Table 24, qRT-PCR program Table 25). All samples were pipetted at least in duplicates 
to ensure reproducibility. 
Table 22: Roche Probe Master reaction set-up 
Component Volume [µl] 
Universal ProbeLibrary probe 0.1 
Primer Mix (10µM each) 0.2 
H2O 0.5 
Roche 480 Probe Master 5 
cDNA 4 
 
Table 23: Roche Probe Master qRT-PCR program 
 T[°C] t[sec] #cycles 
Pre-Incubation 95 600 1 
Amplification 95 10 
50  60 30 
 72 1 
Cooling 20 30 1 
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Table 24: SYBR green qRT-PCR reaction set-up 
Component Volume [µl] 
Primer Mix (10µM each) 0.2 
H2O 2.8 
SYBR Green Master Mix 5 
cDNA 2 
 
Table 25: SYBR green qRT-PCR program 
 T[°C] t[sec] #cycles 
Pre-Incubation 95 600 1 
Amplification 95 15 
50  60 30 
 72 30 
Melting Curve 95 5 
1  65 60 
 97 cont 
Cooling 37   
3.7.4. qRT-PCR data analysis 
For data analysis, the expression of a reference gene was analyzed in parallel with the 
gene of interest: B2M in humans and β-actin for murine samples. The relative expression was 
calculated by applying the formula 2
-Δct
, where Δct is the difference between the threshold 
cycle of the gene of interest and the reference gene. 
3.7.5. SmartSeq2 
RNA was isolated as described above (see section 3.7.1) and the samples were further 
processed for transcriptome analysis using the previously published SmartSeq2 protocol 
(Picelli et al., 2013). Denaturation was performed at 95°C for 2 min in Denaturing Reaction 
Mix (see Table 26) followed by reverse transcription at 42°C for 90 min (see Table 27). For 
pre-amplification, commercially available KAPA HiFi HotStart ReadyMix with 1 nm ISPCR 
primer was used. Cycle conditions are listed in Table 28. The reaction was purified using 
AMPure XP beads and quality was assessed using a Tapestation HighSensitivity D5000 assay 
according to manufacturer’s instructions. Subsequently, the Nextera XT DNA Library 
Preparation Kit was used to prepare the library. Samples were sequenced on an Illumina 
NextSeq 500 instrument using High Output v2 chemistry. RNA-seq data was demultiplexed 
using bcl2fastq2 v2.20 and pseudo aligned to Mus musculus GRCm38 transcriptome using 
kallisto v.0.44.0. Genes that were up- or down-regulated between KO and WT samples were 
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identified (FC > |2.0|, p-value < 0.05, FDR-corrected). Differentially expressed genes were 
compared to a previously published Treg cell signature (Hill et al., 2007) and plotted as a Z-
normalized Heatmap. 
Table 26: Denaturing Reaction-Mix 
Component Amount 
RNA 500pg 
dNTP 0.05M 
anchored oligodT primer 2µM 
RNAse Inhibitor 1U/µl 
Triton X-100 0.1% 
in H2O  
 
Table 27: Reverse Transcription Reaction Mix 
Component Amount 
Template Switching Oligo 1µM 
DTT 5mM 
MgCl2 14mM 
Betaine 1M 
RNAse Inhibitor 1U/µl 
Superscript II reverse transcriptase 5 U/µl 
in 1X Superscript II Buffer  
 
Table 28: Pre-Amplification Cycle Conditions 
 T[°C] t[sec] #cycles 
Pre-Incubation 98 180 1 
Amplification 98 20 
16  67 20 
 72 360 
Cooling 8 hold 1 
3.8. Immunohistochemistry staining of VAT 
VAT was embedded in paraffin, sectioned and stained for F4/80, hematoxylin and 
eosin by the group of C. Wickenhauser from the Institute of Pathology at the University 
Hospital of Halle as described by Eming and colleagues (Eming et al., 2007). 
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3.9. Immunoblotting 
3.9.1. Protein Isolation 
Mice were challenged with 0.5 U/kg bodyweight insulin by intraperitoneal injection 
after a 4 hour fasting period as described in the animal license AZ 84-02.04.2016.A282. Mice 
were sacrificed after 3 min and organs were harvested and flash frozen in liquid nitrogen. 
Subsequently, samples were either stored at -80°C or further processed by transferring the 
tissue into gentleMACS M Tubes with 500µl of either RIPA or MRC buffer supplemented 
with proteinase phosphatase inhibitors. Tissues were dissociated on a gentleMACS dissociator 
using the program ‘m_protein_1’ and incubated on ice for 30 min. Samples were centrifuged 
at 1,000 g for 10 min at 4°C and the supernatant was transferred into a new reaction tube. This 
centrifugation step was repeated three times to remove any traces of fat or tissue remnants. 
To isolate protein from cell suspensions, cells were pelleted and resuspended in RIPA 
buffer supplemented with proteinase inhibitor and, if necessary, phosphatase inhibitor and 
incubated on ice for 30 min. After the incubation, samples were centrifuged at 1,000 g for 10 
min and transferred to a new reaction tube. 
To determine the protein concentration of the resulting sample, the Pierce BCA 
Protein Assay Kit was used according to manufacturer’s instructions. 
3.9.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Between 20 and 50 µg of protein were denatured by adding 5x Laemmli loading buffer 
and incubated at 95°C for 10 min. Samples and a size marker were loaded onto a gel 
consisting of a 10% separation gel overlaid with a 4% stacking gel (For gel composition, see 
Table 29). Electrophoresis was performed at 80 V for 20 min to allow for adequate focusing 
of the protein bands. Subsequently, the voltage was increased to 130 V and continued for 
another hour. 
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Table 29: Reaction set-up for SDS-PAGE gel 
Component 4% stacking gel [V in ml] 10% separation gel [V in ml] 
H2O 1.83 2.01 
1M Tris-HCl (pH 6.8) 0.83 - 
1.5M Tris-HCl 
(pH8.8) 
- 1.25 
10% SDS 0.025 0.05 
30% Acrylamide 0.42 1.67 
10% APS 0.017 0.017 
TEMED 0.003 0.007 
3.9.3. Immunoblotting and detection 
Gels were blotted onto nitrocellulose membranes in wet blotting buffer at 0.2 A for 2 
hours. Subsequently, the membrane was blocked in 5% milk in PBST for 1 hour. The blot 
was incubated overnight in primary antibody, diluted in 5% milk in PBST and subsequently 
washed 3 times for 10 min in PBST followed by incubation in secondary antibody for 1 hour 
at RT in either PBST when using horse-radish-peroxidase (HRP) coupled secondary 
antibodies or in LICOR buffer when using fluorescence coupled secondary antibodies. 
Following the secondary antibody incubation, protein signals were either detected on the 
LICOR Odyssey Imaging System or, when using HRP-conjugated secondary antibodies, 
developed using ECL according to manufacturer’s instructions and imaged on a Chemidoc 
XRS (Bio-Rad). 
If the same blot was probed for a second protein of a similar size, the blot was stripped 
using Re-blot mild solution according to the manufacturer’s instructions. After stripping, the 
blot was blocked in 5% milk in PBST again prior to probing with a different antibody.  
3.9.4. Automated Western Blots 
Samples with limited protein amounts were run on the WES system (Protein Simple), 
a capillary Western blot system with a far lower detection limit than the traditional western. 
WES runs were performed according to manufacturer’s instructions. 
3.10. Genotyping 
For genotyping, ear-clippings were digested at 55°C for at least 1 hour in DirectPCR 
Lysis Reagent Tail (Peqlab) with 0.2 mg/mL Proteinase K according to the manufacturer’s 
instructions. The reaction was stopped by heat inactivation at 85°C for 45 min. Genotyping 
was performed with the MyTaq HS DNA Polymerase (Bioline). 
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3.11. CIBERSORT 
Two publicly available datasets containing PBMC samples from T2D patients as well 
as healthy control patients (GSE9006 and E-MTAB-1954) were analyzed using the 
CIBERSORT (cell-type identification by estimating relative subsets of RNA transcripts) 
algorithm. The algorithm can enumerate immune cell populations based on distinct gene 
signatures and was first published by Newman et al. in 2015 (Newman et al., 2015). 
3.12. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software version 7.0. To 
allow for statistical testing, the number of samples was always at least 3. Statistical 
differences were analyzed using the Student’s t-test or the Mann-Whitney test when analyzing 
differences between two groups. When more than two groups were analyzed, analysis of 
variance (ANOVA) tests were applied. Statistical significance was denoted as n.s. (not 
significant) when p ≥ 0.05, * when p < 0.05, ** when p < 0.005 and *** when p < 0.001. 
Unless otherwise denoted, mean and standard error of the mean (SEM) were depicted. 
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4. Results 
4.1. HPGD is upregulated and enzymatically active in human Treg cells 
Treg cells are vital to maintain control of immune responses and to ensure that immune 
homeostasis is preserved, thus preventing or reducing the induction of autoinflammatory 
diseases. While a lot of research has been conducted to understand the functionality of Treg 
cells, the function of these cells in specific environmental settings, such as the PGE2-rich 
VAT, still remains unclear. Previous work performed by E. Schönfeld and Y. Thabet could 
demonstrate that HPGD, the primary enzyme of PGE2 metabolism, is significantly 
upregulated in human Treg cells compared to Tconv cells (Figure 3 A and B). 
 
Figure 3: HPGD is expressed and enzymatically active in human Treg cells.  
A) Microarray data are published under GEO accession number GSE15390. mRNA 
expression levels of FOPX3 (left panel) and HPGD (right panel) were compared across the 
different experimental conditions. B) Human regulatory and conventional T (Treg and Tconv) 
cells were isolated and relative HPGD mRNA expression was analyzed by qRT-PCR. Mean 
HPGD expression of Tconv cells was normalized to 1. C) Human Treg and Tconv cells were 
cultured in the presence and absence of PGE2 and the accumulation of PGE2 metabolites in 
the supernatant was assessed by enzyme-linked immunosorbent assay. Experiments 
performed by E. Schönfeld and Y. Thabet. FOXP3, Forkhead box protein P3; HPGD, 15-
Hydroxyprostaglandin dehydrogenase  
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E. Schönfeld could show in previously conducted experiments that the upregulation of 
HPGD in human Treg cells occurs in a similar pattern to the regulation of the expression of 
FOXP3, the key transcription factor of Treg cell development, across a variety of experimental 
conditions (Figure 3A). The Treg cell specific expression and the coregulation with FOXP3 
suggests that HPGD might play an important role in Treg cells. 
To determine whether HPGD is enzymatically active in human Treg cells, we analyzed 
the production of PGE2 metabolites when cultivating Treg and Tconv cells in the presence or 
absence of PGE2. We could detect a significant increase in PGE2 metabolites in the 
supernatant of Treg cells cultivated in the presence of  PGE2 compared to both Tconv cells 
cultivated in the presence of PGE2 and to Treg cells cultivated without PGE2 (Figure 3 C). This 
indicates that PGE2 is metabolized when cultivated with Treg cells but not with Tconv cells and 
therefore leads to the conclusion that HPGD is enzymatically active. Thus, we could show 
that HPGD is both upregulated and enzymatically active in human Treg cells. 
4.2. Prostaglandin E2 increases the suppressive capability of human Treg cells 
After confirming that HPGD is both present and enzymatically active in human Treg 
cells, we assessed whether HPGD has an influence on human Treg cell functionality in vitro. 
Thus, we measured the effect of Treg cells on Tconv cell proliferation in the presence of 
different prostaglandins. Cell proliferation was measured by labeling Tconv cells with CFSE 
and then determining the dilution of CFSE on a flow cytometer after 72 hours. 
As expected, when cultivating Tconv cells with increasing ratios of Treg cells, a decrease 
in Tconv cell proliferation could be detected when compared to cultivating only Tconv cells. 
This effect could be increased significantly if PGE2, the PG which is directly metabolized by 
HPGD, was added (Figure 4 A and B). None of the other PGs tested, including PGF2α, PGJ2 
and PGD2 have any effect on the suppression of Tconv cell proliferation (Figure 4 C).  
To confirm this finding, we performed a dose-titration of the different PGs on CD4
+
 T 
cells. After three days of cultivation, we could not detect a significant decrease in 
proliferation caused by any of the other PGs, even when increasing the concentration up to 10 
µM (Figure 4 D). Interestingly, the suppressive effect of PGE2 seems to be dose dependent as 
CD4
+
-cell proliferation was decreased  with increasing amounts of PGE2 added (Figure 4 D). 
Taken together, these results indicate that the suppressive effect, which was only observed 
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when PGE2 was added but not when any of the other PGs were added to the culture, may be 
related to the enzymatic function of HPGD. 
 
Figure 4: Only PGE2 but not any of the other PGs have an effect on Tconv cell proliferation. 
A) Tconv cells were stained with CFSE and cultivated with CD3/CD28 coated beads either 
alone (left panel), with Treg cells (middle panel) or with Treg cells and 1 µM PGE2 (right panel). 
After three days, proliferation was measured on a flow cytometer. B) Quantification of Tconv 
cell proliferation after three days cultivation in the presence of CD3/CD28 coated beads with 
or without 1 µM PGE2 at different Tconv to Treg cell ratios as a function of CFSE dilution. C) 
Quantification of Tconv cell proliferation after three days cultivation in the presence of 
CD3/CD28 coated beads with or without 1 µM different PGs at different Tconv to Treg cell 
ratios as a function of CFSE dilution. D) Effect of dose titration of different PGs on the 
proliferation of CD4+ T cells after three days of cultivation as a function of CFSE dilution. 
Experiments were partially carried out by Y. Thabet. 
Previously, we analyzed the effect of the different PGs on T-cell proliferation only in 
the presence of Treg cells. However, to determine whether Treg cells are necessary to mediate 
the suppressive function of PGE2, we analyzed the effect of PGE2 on Tconv cells in the absence 
of Treg cells. As expected, when PGE2 was added to the entire CD4
+
 T cell population, 
containing both Treg and Tconv cells, proliferation was inhibited (Figure 5 A, top panel). 
However, when Treg cells were removed from the population by magnetic depletion of CD25 
expressing cells, PGE2-mediated suppression of Tconv cell proliferation was greatly reduced 
(Figure 5 A, bottom panel, and B). This indicates that Treg cells are clearly necessary for the 
PGE2 dependent suppression mechanism. 
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Figure 5: The presence of PGE2 hampers T-cell proliferation in the presence of Treg cells. 
A) CD4+ T cells (top panel) or Tconv cells (bottom panel) were stained with CFSE and cultivated 
with CD3/CD28 coated beads in the presence of absence of 1 µM PGE2. CFSE dilution was 
measured on by flow cytometry. B) Quantification of the suppressive effect of 1 µM PGE2 on 
the proliferation of CD4+ cells vs. Tconv cells as a function of CFSE dilution. Experiments were 
partially performed by Y. Thabet. 
In order to determine whether HPGD is directly involved in the decreased Tconv cell 
proliferation conferred by PGE2, we analyzed the effect of the HPGD-generated PGE2 
metabolite 15-keto-PGE2 on Tconv proliferation in the presence and absence of Treg cells. Just 
like PGE2, the metabolite suppresses the proliferation of CD4
+
 T cells (Figure 6 A, top panel) 
in a dose dependent manner (Figure 6 B). However, unlike the effect propagated by PGE2, 15-
keto-PGE2 can also hamper Tconv cell proliferation in the absence of Treg cells (Figure 6 A, 
bottom panel, and B). When comparing the suppressive effect of PGE2 and 15-keto-PGE2 on 
the proliferation of Tconv cells in the presence of Treg cells, no significant difference was 
observed (Figure 6 C). This indicates that the observed suppressive effect is not, in fact, 
caused directly by PGE2 but rather by the metabolism of PGE2 into 15-keto-PGE2 by HPGD 
expressing Treg cells. 
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Figure 6: 15-keto-PGE2 suppresses Tconv cell proliferation even in the absence of Treg cells. 
A) CD4+ T cells (top panel) or Tconv cells (bottom panel) were stained with CFSE and 
cultivated with CD3/CD28 coated beads in the presence or absence of 10 µM 15-keto-PGE2 
for three days. CFSE dilution was measured on a flow cytometer. B) Dose titration of the 
suppressive effect of 15-keto-PGE2 on the proliferation of CD4
+ T cells as a function of CFSE 
dilution. C) Quantification of Tconv cell proliferation after three days of cultivation in the 
presence of CD3/CD28 coated beads with 1 µM PGE2, with 10 µM 15-keto-PGE2 or without 
PGs at different Tconv to Treg cell ratios as a function of CFSE dilution. Experiments were 
partially performed by Y. Thabet. 
To further support that 15-keto-PGE2 is the metabolite which is responsible for the 
increased suppressive capability of Treg cells in the presence of PGE2, we analyzed the 
expression of the two main enzymes of 15-keto-PGE2 metabolism: Prostaglandin reductase 
(PTGR) 1 and 2. While both enzymes could be detected in myeloid cells, we could not detect 
PTGR1 mRNA (Figure 7A) and only relatively low levels of PTGR2 (Figure 7B) in either the 
Treg or the Tconv cell populations, suggesting that 15-keto-PGE2 and not a further metabolite is 
responsible for the suppressive effect. 
Thus, we could show that HPGD is involved in the suppressive function of human Treg 
cells by metabolizing PGE2 into 15-keto-PGE2 and that the metabolite is sufficient to elicit the 
suppressive effect on Tconv cell proliferation. Furthermore, due to the absence of metabolizing 
enzymes, we hypothesize that 15-keto-PGE2 directly acts on Tconv cells. 
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Figure 7: The 15-keto-PGE2 metabolizing enzymes, PTGR1 and PTGR2, are only expressed 
at low levels in CD4+ T cells compared to cells of the myeloid compartment. 
Monocytes, macrophages, dendritic cells, Tconv and Treg cells were isolated or differentiated 
from human blood. qRT-PCR was performed on A) PTGR1 and B) PTGR2. Mono, Monocytes; 
MΦ, Macrophages; DC, Dendritic cells; PTGR, Prostaglandin reductase; n.d., not detectable 
4.3. Hpgd expression and functionality is conserved in the mouse 
As a subsequent step, we wanted to analyze the role of HPGD in Treg cells in vivo to 
better determine the systemic effect of HPGD for Treg cell functionality, especially in the 
context of PGE2-rich microenvironments, such as the VAT. To allow for this, we had to 
change from humans to the murine model system. To determine the suitability of the murine 
system for analyzing the role of Hpgd in Treg cells, we first wanted to confirm that Hpgd is 
similarly upregulated in murine Treg cells. Therefore, we isolated T cells from the spleen, the 
mesenteric lymph nodes (mLN), the peripheral lymph nodes (pLN), BM and peripheral blood 
(PB) and measured Hpgd mRNA expression by qRT-PCR. We could detect both a significant 
upregulation of Hpgd (Figure 8 A) and of Foxp3 (Figure 8 B) in Treg cells compared to Tconv 
cells in all analyzed organs, similar to the upregulation of HPGD in human Treg cells.  
To further evaluate the role of Hpgd in Treg cells, we crossed two previously published 
mouse lines: one with a loxP flanked exon 1 at the Hpgd locus (Roizen et al., 2008) and one 
with a YFP-Cre inserted into the 3’ untranslated region of the Foxp3 locus under the control 
of an IRES site (Rubtsov et al., 2008) (Appendix Figure 52 A and C). Crossing these two 
lines homozygously for the floxed Hpgd locus and homo- or hemizygously for the Foxp3 
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locus leads to the deletion of Hpgd selectively in Treg cells and the expression of an YFP 
reporter in all Treg cells. Littermates heterozygous for the floxed Hpgd allele were used as 
wildtype (WT) controls. 
 
Figure 8: Hpgd and Foxp3 are significantly upregulated in murine Treg cells compared to 
Tconv cells. 
Treg and Tconv cells were isolated from the spleen, mesenteric and peripheral lymph nodes 
(mLN and pLN), peripheral blood (PB) and bone marrow (BM). A) Hpgd and B) Foxp3 
expression was determined by qRT-PCR. 
Since it has been previously reported that the Foxp3-Cre line can exhibit some 
unspecific Cre-activity in cells outside of the Treg cell lineage (Franckaert et al., 2015), we 
first analyzed the specificity of the deletion by PCR on genomic DNA isolated from Treg and 
Tconv cells homozygous and heterozygous for the floxed Hpgd allele. Using a 3-primer PCR 
enabled us to differentiate between the wildtype, the conditional and the recombined allele 
(Figure 9 A). When analyzing Hpgd
FL/FL
 Foxp3-Cre and Hpgd
FL/WT 
Foxp3-Cre mice, we could 
clearly detect the wildtype allele only in mice heterozygous for the floxed Hpgd locus. 
Furthermore, the Tconv cell samples samples mainly expressed the conditional allele while Treg 
cells mainly expressed the band for the recombined allele (Figure 9 B; quantified in C). This 
shows that even though we could detect some unspecific Cre-activity in Tconv cells, this 
activity is negligible especially when considering that Tconv cells do not express Hpgd at 
significant levels. 
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Figure 9: Genomic analysis of the Hpgd locus of HpgdFL/FL Foxp3-Cre and Hpgd
FL/WT Foxp3-
Cre animals showed only limited recombination in Tconv cells.  
A) Schematic illustration of the PCR of the genomic Hpgd locus for the wildtype (top), 
conditional (middle) and recombined (bottom) allele. B) Gel image and C) quantification of 
PCR data for the genomic Hpgd locus of Treg and Tconv cells isolated from Hpgd
FL/FL
 Foxp3-Cre 
and HpgdFL/WT Foxp3-Cre mice. WT, wildtype; FL floxed. 
To confirm that Hpgd functions in a similar manner in the mouse as in humans, we 
performed suppression assays with murine Treg cells in the presence and absence of PGE2. As 
in humans, the presence of PGE2 augmented the suppressive capabilities of the murine Treg 
cells (Figure 10 A). This effect cannot be observed, however, when Hpgd-deficient (KO) Treg 
cells were used in the suppression assay (Figure 10 B). This indicates that the increased 
suppressive effect observed in the presence of PGE2 is truly caused by the presence of Hpgd 
in Treg cells and that the role of Hpgd for the suppressive capabilities of Treg cells is conserved 
between mouse and man. 
 
Figure 10: PGE2 only increases the suppressive effect of murine Treg cells if they express 
Hpgd. 
Quantification of Tconv cell proliferation after three days of cultivation in the presence of 
CD3/CD28 coated beads with or without 1µM PGE2 with increasing A) WT Treg or B) Hpgd-
deficient Treg to Tconv ratios as a function of eFlour670 dilution. Experiments performed by Y. 
Thabet. KO, knock out 
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4.3.1. Analysis of Treg cell functionality in vivo 
Since we so far only analyzed the effect of Hpgd in in vitro assays, we assessed 
whether a loss of Hpgd in Treg cells also influences the suppressive capabilities of Treg cells in 
vivo. Therefore, we performed dextran sodium sulfate (DSS)-driven colitis experiments by 
administering DSS, a water soluble, negatively charged polysaccharide, to mice in drinking 
water. Within six days, this leads to the induction of colitis. Even though the exact mechanism 
of colitis induction is unclear, it is widely assumed that DSS damages the large intestine, 
causing proinflammatory intestinal content, such as bacteria, to enter the tissue and cause 
inflammation (Chassaing et al., 2014). Thus, disease severity can be linked to the ability of 
Treg cells to suppress inflammation. 
 
Figure 11: Hpgd-deficient Treg cells are less efficient in attenuating DSS colitis. 
A) Mice with wild type (WT) and Hpgd-deficient Treg cells were given free access to either 
water or water supplemented with 5% (w/v) DSS for 6 days. Animals were weighed daily. B) 
PGE2 content of colons and serum of diseased animals was measured by mass 
spectrometry, performed in the Institute of Clinical Pharmacology, Frankfurt by N. Ferreirós. 
Colitis was induced both in WT and KO animals when DSS was administered, as 
measured by an increased weight loss compared to control groups which only received water 
(Figure 11 A). However, we could detect a significantly higher weight loss in animals with 
Hpgd-deficient Treg cells compared to WT littermate controls, indicating that Treg cells which 
lack Hpgd are less efficient in attenuating the development of DSS colitis (Figure 11 A). As 
expected, when measuring the PGE2 concentrations by mass spectrometry in the colon and 
serum of animals with WT and KO Treg cells subjected to DSS colitis by mass spectrometry, a 
significantly higher accumulation of PGE2 could be observed in the KO animals compared to 
WT littermate controls (Figure 11 B). This indicates that the increased development of colitis 
may be caused by the reduced metabolism of PGE2 into 15-keto-PGE2 caused by a loss of 
Hpgd, which leads to an accumulation of PGE2 and a decrease in the suppressive capabilities 
of the Treg cells, thus increasing disease severity. 
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Figure 12: Hpgd-deficient Treg cells are less efficient in preventing the development of 
adoptive transfer colitis. 
A) Weight curve and B) colon length of Rag-2-/- animals injected with naïve T cells, naïve T 
cells and WT Treg cells or naïve T cells and Hpgd-deficient Treg cells. C) Hematoxylin and eosin 
stain of colons isolated from Rag-2-/- animals injected with naïve T cells, naïve T cells and WT 
Treg cells or naïve T cells and Hpgd-deficient Treg cells and D) histological score thereof. 
Histology was performed at the Institute for Pathology, University Hospital Halle by C. 
Wickenhauser. Tnaive, naïve T cells.
To analyze the role of T cells, more specifically Treg cells, in the development of 
colitis more closely, we performed adoptive transfer colitis experiments. In classical adoptive 
transfer experiments, as pioneered by the lab of Fiona Powrie, naïve T cells are transferred 
into mice which lack B or T cells (Ostanin et al., 2009). For this, animals whose Rag-2 coding 
region was deleted (Rag-2
-/-
) and who therefore can no longer produce B- or T-cells since 
they lack V(D)J recombination activity (Shinkai et al., 1992) are used as the recipient animals 
(Appendix, Figure 52 E). Due to the transfer of naïve T cells, the mice develop colitis, 
characterized by severe weight loss, infiltration of leukocytes in the colon, crypt abscesses 
and epithelial cell erosion (Coombes et al., 2005). One major advantage of this model is that it 
is ideal to study the effect of Treg cells in an inflammatory setting by transferring Treg cells in 
addition to naïve T cells and thus preventing or at least alleviating the onset of colitis (Izcue et 
al., 2006). 
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As expected, when we injected Rag-2
-/-
 animals with naïve T cells, the animals 
developed colitis as characterized by severe weight loss. However, when WT Treg cells were 
transferred in addition to naïve T cells, the animals no longer lost any weight, indicating that, 
as expected, Treg cells could prevent the onset of colitis. When replacing the WT Treg cells 
with KO Treg cells, the animals still developed colitis (Figure 12 A). However, the disease 
severity was significantly reduced from Rag-2
-/-
 animals which only received naïve T cells as 
determined by severity of weight loss (Figure 12 A), reduction of colon length (Figure 12 B) 
and histological score of colon tissue sections (Figure 12 C and D). 
An analysis of absolute cell numbers of animals injected with naïve T cells, naïve T 
cells and WT Treg cells or naïve T cells and Hpgd-deficient Treg cells in spleen (Figure 13 A) 
and mLNs (Figure 13 B) showed that the number of Tconv cells was significantly reduced in 
both organs when Treg cells were also injected compared to when only naïve T cells were 
introduced to the animals. However, this reduction is greatly reduced when Hpgd-deficient 
Treg cells are introduced instead of WT Treg cells, further indicating that Hpgd-deficient Treg 
cells are less efficient in preventing Tconv cell proliferation also in vivo. 
 
Figure 13: Hpgd-deficient Treg cells are not as efficient in preventing Tconv cell proliferation 
in the adoptive transfer colitis model. 
Tconv (left panel) or Treg (right panel) cell numbers after induction of adoptive transfer colitis 
with naïve T cells, naïve T cells and WT Treg cells or naïve T cells and Hpgd-deficient Treg cells 
in A) spleen and B) mLN. 
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Next, we evaluated whether the loss of Hpgd in the animals led to decreased viability 
of the Treg cells and whether the viability of the Treg cells may influence the increased 
development of colitis. However, we found that the reduced ability of Hpgd-deficient Treg 
cells to prevent the induction of colitis is not due to reduced viability or proliferation of the 
Treg cells themselves as the number of Treg cells is significantly increased in both the spleen 
and the mLNs when KO Treg cells were injected instead of WT Treg cells (Figure 13A and B, 
right panel). This accumulation of Hpgd-deficient Treg cells may be a compensatory 
mechanism to make up for their reduced suppressive functionality. 
Taken together these results indicate that Hpgd expression in Treg cells is necessary for 
the effectual functionality of Treg cells in vivo as a loss of Hpgd in Treg cells leads to increased 
disease development both in DSS and adoptive transfer colitis. 
4.3.2. 15-keto-PGE2 suppresses Tconv cell proliferation via Ppar-γ signaling  
In humans, we could show that the effect of PGE2 on the proliferation of Tconv cells 
was mediated by the HPGD-dependent metabolism of PGE2 into 15-keto-PGE2 (Figure 6). To 
further analyze the role of 15-keto-PGE2, we first evaluated whether the suppressive 
capability of the metabolite is conserved in the mouse. We observed that, just like in humans, 
15-keto-PGE2 can inhibit Tconv cell proliferation in a dose dependent manner even in the 
absence of Treg cells (Figure 14 A and B). 
 
Figure 14: 15-keto-PGE2 can inhibit murine Tconv cell proliferation even in the absence of 
Treg cells. 
A) Tconv cells were stained with CFSE and cultivated with CD3/CD28 coated beads in the 
presence of absence of 10 µM 15-keto-PGE2 for three days. CFSE dilution was measured by 
flow cytometry. B) Effect of increasing amounts of 15-keto-PGE2 on the proliferation of Tconv 
cells as a function of CFSE dilution. Experiments were conducted by Y. Thabet. 
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15-keto-PGE2 has previously been implicated as a ligand of Ppar-γ (Chou et al., 2007). 
However, it has proven difficult to definitively identify receptor ligands, especially for 
nuclear receptors (Schupp and Lazar, 2010), since studies showing in vitro binding often 
cannot be confirmed in vivo. For instance, while 15-deoxy-Δ12,14-PGJ2 has been shown to be a 
Ppar-γ ligand it has later been determined that endogenous levels of 15-deoxy-Δ12,14-PGJ2 
were too low to effectively act as a Ppar-γ ligand (Bell-Parikh et al., 2003; Forman et al., 
1995). Furthermore, the ligand binding domain of Ppar-γ is relatively large (Nolte et al., 
1998), thus allowing the binding of many, structurally distinct ligands and making effective 
ligand prediction difficult. 
 
Figure 15: Stimulation with 15-keto-PGE2 leads to an upregulation of genes downstream 
of Ppar-γ in differentiated 3T3-L1 cells and bone marrow-derived macrophages (BMDMs).  
3T3-L1 cells were differentiated into adipocytes and stimulated overnight with 1 µM 15-
keto-PGE2, Rosiglitazone or DMSO as vehicle control. Ppar-γ activation was determined by 
measuring A) Ap2 and B) Angptl4 mRNA expression by qPCR. C) BMDMs were stimulated 
overnight with 15-keto-PGE2, Rosiglitazone or DMSO as vehicle control. Ppar-γ activation 
was determined by measuring Angptl4 mRNA expression by qPCR. Angptl4, angiopoietin-
like 4; Ap2, Adipocyte protein 2; Rosi, Rosiglitazone 
Therefore, we attempted to confirm that 15-keto-PGE2 is a Ppar-γ ligand by using the 
common 3T3-L1 assay for Ppar-γ ligand activation (Watanabe et al., 2003). 3T3-L1 cells 
were differentiated into adipocytes and then stimulated with the Ppar-γ ligand Rosiglitazone 
as a positive control, DMSO as vehicle control, as well as 15-keto-PGE2. To assess ligand 
binding and Ppar-γ activation, the transcription of adipocyte protein 2(Ap2) and angiopoietin-
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like protein 4 (Angptl4), two genes directly downstream of Ppar-γ, were assessed by qPCR. 
We could detect a significant upregulation of both Ap2 (Figure 15 A) and Angptl4 (Figure 15 
B) after 15-keto-PGE2 or Rosiglitazone stimulation in comparison to control samples treated 
only with DMSO. 
However, this system is a very artificial method of measuring Ppar-γ activation. 
Therefore, we also analyzed the effect of DMSO, 15-keto-PGE2 or Rosiglitazone stimulation 
on BMDMs and could detect a significant upregulation of Angptl4 in these cells in 
comparison to cells only stimulated with vehicle control (Figure 15 C), indicating that 15-
keto-PGE2, like Rosiglitazone, can activate the Ppar-γ-dependent transcriptional program. 
 
Figure 16: 15-keto-PGE2 and Rosiglitazone inhibit the differentiation of bone marrow-
derived dendritic cells (BMDCs) into mature DCs. 
BMDCs were differentiated in the presence of 1 µM 15-keto-PGE2, Rosiglitazone or DMSO 
as vehicle control. Differentiation of cells was assessed by determining the MFI of A) CD11c, 
B) CD14 or C) MHC-II by flow cytometry. MHCII, major histocompatibility complex II 
In a subsequent step, we analyzed the effect of 15-keto-PGE2 on the differentiation 
process of BMDCs since it has been previously shown that BMDCs cultivated in the presence 
of Rosiglitazone show a severe impairment in their ability to differentiate into mature BMDCs 
(Byun et al., 2016). To confirm that 15-keto-PGE2 acts on BMDCs in a similar manner, we 
added either 15-keto-PGE2, Rosiglitazone or DMSO to BMDC cultures and evaluated their 
ability to differentiate into mature BMDCs by flow cytometry. We could show that the 
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expression of CD11c, our surrogate marker for BMDC differentiation, was downregulated in 
cells stimulated with 15-keto-PGE2 or Rosiglitazone compared to cells stimulated with 
DMSO as vehicle control (Figure 16 A). Further, we could detect an upregulation of the 
monocytic marker CD14 (Figure 16 B), while MHC-II expression levels remained constant, 
despite 15-keto-PGE2 or Rosiglitazone stimulation (Figure 16 C), confirming once again that 
15-keto-PGE2 acts in a manner similar to the well-described Ppar-γ agonist Rosiglitazone and 
that, as previously published (Chou et al., 2007), 15-keto-PGE2 can act as a Ppar-γ ligand. 
Since we could show that 15-keto-PGE2 can act in different immune cells via Ppar-γ 
signaling in a manner reminiscent of the Ppar-γ agonist Rosiglitazone, we analyzed whether 
the observed suppressive effect of 15-keto-PGE2 on Tconv cell proliferation is also Ppar-γ 
dependent. Therefore, we generated mice whose CD4
+
 T cells do not express Ppar-γ by 
crossing a mouse with a Cre-recombinase inserted after the CD4 promoter (Lee et al., 2001) 
to a mouse carrying a floxed Pparg allele (Akiyama et al., 2002) (Appendix Figure 52 B and 
D). 
 
Figure 17: The suppressive effect of 15-keto-PGE2 is partially dependent on Ppar-γ 
signaling.  
A) Ppar-γ-sufficient (upper panel) and deficient (lower panel) Tconv cells were stained with 
CFSE and cultivated with CD3/CD28 coated beads in the presence of absence of 10 µM 15-
keto-PGE2 for three days. CFSE dilution was measured on by flow cytometry. B) Effect of 
increasing doses of 15-keto-PGE2 on the proliferation of WT and Ppar-γ-deficient Tconv cells 
as a function of CFSE dilution. Experiments were conducted by Y. Thabet. 
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When adding 15-keto-PGE2 to Ppar-γ-deficient Tconv cells, we could observe that the 
suppressive effect of the metabolite was significantly reduced (Figure 17 A and B). However, 
the effect was only partial as we could still observe a dose-dependent decrease in Tconv cell 
proliferation even in Ppar-γ-deficient Tconv cells (Figure 17 B). This indicates that while 15-
keto-PGE2 seems to at least partially act through Ppar-γ signaling, this is not the only manner 
in which 15-keto-PGE2 suppresses Tconv cell proliferation. 
4.3.3. Hpgd expression in Treg cells is important for immune cell homeostasis 
in VAT of aged mice. 
Since Ppar-γ has been shown to be vital to maintain healthy metabolic signaling and 
homeostasis and is further clearly associated with the VAT-associated transcriptional program 
of Treg cells, we hypothesized that Hpgd might also be involved in the governance of 
metabolic processes. Further evidence that PGE2, and therefore also the PGE2 metabolizing 
enzyme, Hpgd, might play an important role in the VAT is the high expression of COX-1, a 
central enzyme in the metabolic pathway of PGE2 (Figure 1), in VAT (Hétu et al., 2007). 
Therefore, we studied the role of Hpgd expressing Treg cells in the VAT as well as their role in 
immune and metabolic homeostasis.  
When analyzing Hpgd levels in VAT in comparison to other tissue resident Treg cells, 
we could clearly show that, while Hpgd is upregulated in all tissue Treg cells, its expression is 
about 20-fold elevated in VAT Treg cells compared to Tconv cells while in all other organs the 
Hpgd expression in Treg cells is only elevated between 0.5 – 3-fold (Figure 18).  
 
Figure 18: Hpgd is highly expressed in VAT Treg cells. 
Treg  and Tconv cells were isolated from the VAT, kidney, lung, spleen, mesenteric lymph 
nodes and bone marrow of WT animals and Hpgd mRNA expression was determined by 
qRT-PCR. Mean Tconv expression was normalized to 1. 
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Figure 19: Treg cell fractions are significantly increased in aged animals with Hpgd-deficient 
Treg cells. 
Analysis of the CD4+ Foxp3+ Treg cell fraction by flow cytometry in A) spleen and B) VAT of 
animals with Hpgd-deficient and WT Treg cells. C) Representative dot plots of VAT Treg cell 
populations in 80-week old animals with Hpgd-deficient (right) and WT Treg cells. D) Analysis 
of absolute numbers of Treg cell populations in VAT of 80-week old animals with WT and 
Hpgd-deficient Treg cells. Analysis of the CD4
+ Foxp3+ Treg cell fraction in aged animals with 
Hpgd-deficient and WT Treg cells in E) the lung, F) the skin and G) the colon. 
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As has been previously described, deficiencies in Treg cell function either take effect 
immediately in the so-called scurfy phenotype, a fatal and systemic autoimmune disease 
(Godfrey et al., 1991; Sharma et al., 2009), or only develop as the animal ages (Fessler et al., 
2013; Huynh et al., 2015; Raynor et al., 2012; Shrestha et al., 2015). Therefore, we analyzed 
Treg cell populations in young and aged mice. As expected, we could detect an age-related 
increase in the Treg cell population both in the spleen (Lages et al., 2008) and in the VAT 
(Cipolletta et al., 2015) (Figure 19 A and B). This age-related increase was much more 
pronounced in Hpgd-deficient Treg cells of the VAT, leading to a significant increase in VAT-
resident Treg cells in 80 week old animals with Hpgd-deficient Treg cells when compared to 
WT littermates (Figure 19 B and C). This difference remains significant both when analyzing 
relative and absolute Treg cell numbers (Figure 19 C and D). This observation is VAT specific, 
as we could not observe such an increase in any other lymphoid or non-lymphoid organ we 
analyzed, including the spleen (Figure 19 A), the lung (Figure 19 E), the skin (Figure 19 F) 
and the colon (Figure 19 G). Furthermore, we could not detect a difference in Treg cell 
accumulation in female animals of the same age (data not shown). 
Since we could observe a significant increase in Treg cells in the VAT of animals with 
Hpgd-deficient Treg cells, we wanted to analyze whether this increase is caused by enhanced 
proliferation. Therefore, we analyzed the expression of the proliferation marker Ki-67 by flow 
cytometry and could observe a significant upregulation of Ki-67 in Hpgd-deficient VAT-Treg 
cells compared to their WT counterparts (Figure 20 A and B). Such an increase has previously 
been associated with increased inflammation in VAT (Kolodin et al., 2015). Next, we 
analyzed Ki-67 expression in splenic Treg cells deficient for Hpgd (Figure 20 C) and could not 
detect a significant increase in Ki-67 expression of splenic Treg cells, even though we could 
detect a trend towards increased Ki-67 expression in Hpgd-deficient Treg cells. This indicates 
that the observed increase in the VAT-resident Hpgd-deficient Treg cell population is most 
likely caused by local proliferation of Treg cells and not by a generally increased proliferation 
of Treg cells in secondary lymphoid organs. 
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Figure 20: Ki-67 is significantly upregulated in Hpgd-deficient VAT-resident Treg cells of 
aged animals.  
A) Histograms of Ki-67 expression in VAT-resident WT and Hpgd-deficient Treg cells and B) 
quantification thereof. C) Quantification of Ki-67 expression in splenic WT and Hpgd-
deficient Treg cells. 
Subsequently, we analyzed whether the observed increase in VAT-Treg cells in animals 
with Hpgd-deficient Treg cells correlates with an increase in absolute VAT mass. However, 
when analyzing the weight of the VAT in these animals, we could not detect any difference 
(Figure 21 A). Further, no difference in splenic weight or overall bodyweight (Figure 21 B 
and C) could be detected, indicating that the observed increase in the Treg cell population in 
the VAT is an absolute increase and not caused by increased body or organ weight. 
 
Figure 21: No significant difference in VAT, splenic or body weight between aged animals 
with Hpgd-deficient Treg cells and age-matched littermate controls.  
A) VAT, B) splenic and C) body weight of aged animals with Hpgd-deficient Treg cells and WT 
littermate controls. 
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To analyze how the loss of Hpgd in Treg cells would impact the phenotype and 
transcriptional identity of Treg cells, we analyzed several typical Treg cell markers such as 
CTLA-4, GITR, and Helios in both the WT and KO Treg cell populations of the spleen (Figure 
22 A) or the VAT (Figure 22 B) and observed no differences. Moreover, when analyzing the 
VAT-specific Treg marker ST2, we also could not detect any difference (Figure 22 B). 
Since we could observe a decrease in suppressive Treg cell function coupled with an 
increase in the VAT-resident Treg cell population of aged KO animals, we hypothesized that 
this increase in the Treg cell population may be caused by a compensatory effect and be linked 
to increased VAT inflammation. Therefore, we analyzed the VAT-resident myeloid 
population of these animals. 
 
Figure 22: Phenotypic characterization of splenic and VAT-resident, Hpgd-deficient or WT 
Treg cells of aged animals.  
Quantification of classical Treg cell associated marker protein in A) splenic and B) VAT-
resident Treg cells isolated from aged animals with WT and Hpgd-deficient Treg cells. CTLA-4, 
cytotoxic T-lymphocyte-associated Protein 4; GITR, glucocorticoid-induced TNFR family 
related gene; Nrp1, Neuropilin-1; KLRG1, killer-cell lectin like receptor G1. 
We could detect an increased infiltration of macrophages in the VAT of aged animals 
with KO Treg cells by flow cytometry (Figure 23 A and B). Further analysis of the 
macrophage population showed that the macrophages are mainly pro-inflammatory in nature, 
as characterized by the increased expression of the marker CD11c (Figure 23 C). 
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Furthermore, we analyzed the infiltrating granulocytes in the VAT of aged KO animals, since 
an increase in granuolcytes has been linked to obesity, metabolic dysregulation and increased 
adipose tissue inflammation (Huh et al., 2014; Talukdar et al., 2012). However, we could not 
detect a difference in the VAT-resident granulocyte population of aged KO compared to WT 
animals. 
 
Figure 23: Aged animals harboring Hpgd-deficient Treg cells show increased infiltration of 
proinflammatory macrophages in the VAT.  
A) Representative dot plot and B) quantitative analysis of macrophage population in the 
VAT of aged animals with KO Treg cells or WT littermate controls. Quantitative analysis of C) 
the proinflammatory macrophage population and D) the granulocyte population in the VAT 
of these animals. 
To confirm this increased infiltration of myeloid cells, histological analyses of the 
VAT of aged animals with KO Treg cells and of age matched littermate controls were 
performed by the laboratory of C. Wickenhauser. We could confirm the previously observed 
significant increase in macrophage infiltration in the VAT of aged animals with KO Treg cells 
as compared to WT littermate controls (Figure 24 A and B). Furthermore, we detected a 
striking increase in adipocyte size in these animals (Figure 24 A and C). These observations 
are further indicative of increased inflammation in the VAT of aged animals with KO Treg 
cells. 
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In contrast, in aged female mice, we could not detect any differences in the VAT-
resident immune cell compartment (Figure 25 A-C), a not unexpected observation as it has 
been previously described that the makeup of the VAT-resident immune cell compartment of 
female mice differs from that of male animals (Ahnstedt et al., 2018).  
 
Figure 25: No difference in the VAT-resident Treg or macrophage population could be 
detected between aged female mice with Hpgd-competent or deficient Treg cells. 
Quantitative analysis of the A) Treg cell B) macrophage and C) inflammatory macrophage 
population in the VAT of aged female animals with Hpgd-deficient Treg cells or WT littermate 
controls. 
 
Figure 24: Aged animals with Hpgd-deficient Treg cells show an increased infiltration of 
macrophages and adipocyte size in VAT.  
A) Histological analysis of VAT of aged animals with KO Treg cells and WT littermate control 
animals stained for F4/80 (purple). Quantitative analysis of B) macrophages per high power 
field and C) size of adipocytes in VAT of aged animals with Hpgd-deficient Treg cells and WT 
littermate control animals. Histology was performed in the Institute for Pathology in Halle 
by C. Wickenhauser. 
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All in all, we could observe an age-related increase of Treg cells in the VAT of male 
animals with a Treg cell specific deletion of Hpgd. Despite being unable to detect a phenotypic 
change in these Treg cells, we could observe an increase in inflammation in the VAT of 
animals with Hpgd-deficient Treg cells as shown, for instance, by an increased 
proinflammatory macrophage accumulation. 
4.3.4. Hpgd expression in Treg cells is dependent on Ppar-γ signaling 
Since we could observe that the suppressive effect of Hpgd is at least partially 
mediated by the Ppar-γ ligand 15-keto-PGE2, we subsequently analyzed the effect of Ppar-γ 
signaling on Treg cell biology by selectively deleting Ppar-γ only in Treg cells. This was 
achieved by crossing animals with floxed Ppar-γ (Akiyama et al., 2002) to animals expressing 
the Cre-recombinase in a Foxp3 dependent manner (Rubtsov et al., 2008) (Appendix Figure 
52 B and C) and analyzing Hpgd expression in Treg cells isolated from these animals. While 
we could observe Hpgd expression in Treg cells isolated from WT control animals, Hpgd 
levels were decreased in Treg cells deficient for Ppar-γ independent on whether the Treg cells 
were isolated from LNs (Figure 26 A), the spleen (Figure 26 B) or from VAT (Figure 26 C). 
This seems to indicate that Ppar-γ signaling is necessary for Hpgd expression and thus that 
Hpgd is downstream of Ppar-γ. 
 
Figure 26: Ppar-γ dependent expression of Hpgd  
Treg cells were isolated from A) mLN, B) spleen and C) VAT of WT animals and animals with 
Ppar-γ-deficient Treg cells and Hpgd mRNA levels were determined by qRT-PCR. 
4.3.5. Loss of Hpgd leads to mainly extrinsic effects in Treg cells 
To further analyze potential differences between WT and KO Treg cells, we 
performed transcriptome analysis of Treg and Tconv cells isolated from both the spleen and 
the VAT to determine whether the deletion of Hpgd in Treg cells affects the general or VAT-
resident Treg cell signature. 
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Therefore, we performed RNA-seq of splenic Treg cells of aged WT and KO animals. 
We could not detect any major differences between the KO and WT Treg cells when 
performing t-SNE analysis of variable genes (Figure 27 A). Furthermore, when comparing 
expression against the murine Treg cell signature (Hill et al., 2007), we could not detect any 
major differences in the expression of core-Treg genes between Hpgd-competent and deficient 
Treg cells (Figure 27 B). 
 
Figure 27: No major transcriptomic differences between splenic WT and Hpgd-deficient 
Treg cells could be detected.  
Transcriptome analysis of Treg and Tconv cells isolated from the spleen of least three animals 
harboring Hpgd-deficient or WT Treg cells. A) t-SNE analysis based on variably expressed 
genes and B) heat map of selected genes from the murine Treg cell signature (Hill et al., 
2007). 
Similarly, when analyzing VAT-resident Treg cells, we could not detect any overt 
differences in gene expression between VAT-resident WT and KO Treg cells, as evidenced by 
close proximity of WT and KO Treg cells in a t-SNE analysis (Figure 28 A) or in their 
expression of VAT Treg cell signature genes (Figure 28 B), thus further supporting that the 
core program of these cells is not disturbed by the deletion of Hpgd. In summary, this 
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indicates that the observed effects of a Treg specific deletion of Hpgd are not of an intrinsic 
nature but rather caused by the loss of the enzymatic action of Hpgd. 
 
Figure 28: No difference in the transcriptome between VAT WT and Hpgd-deficient Treg 
cells could be detected. 
Transcriptome analysis of Treg and Tconv cells isolated from the spleen of least three animals 
harboring Hpgd-deficient or WT Treg cells. A) t-SNE based on variably expressed genes and 
B) heat map of selected genes from the murine VAT Treg cell signature. 
To further validate our hypothesis, we performed adoptive colitis experiments where 
we transferred Hpgd-deficient or sufficient Treg cells in combination with WT naïve T cells 
into Rag-2
-/- 
animals. We co-transferred RFP-expressing WT Treg cells to prevent the onset of 
colitis, which cannot be completely ablated by the transfer of KO Treg cells (See Figure 12) 
This enabled us to analyze differences between WT and Hpgd-deficient Treg cells 
independently of any effects caused by any functional differences caused by the loss of Hpgd 
resulting in the onset of disease (Figure 29 A). We observed the animals for 8 weeks after 
injection and could detect no development of colitis in animals transfected with Treg cells 
while animals injected only with naïve T cells experienced colitis (Figure 29 B). We 
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sacrificed the animals 8 weeks after injection and isolated Treg cells from the mLN and could 
not detect a difference in the number of Treg cells recovered between animals injected with 
WT and KO Treg cells (Figure 29 C) or in the ratio of YFP to RFP positive Treg cells (Figure 
29 D). Furthermore, transcriptome analysis of these cells did not reveal any significant 
differences in their gene expression profile (Figure 29 E). Taken together, these data seem to 
indicate that the Treg cell specific deletion of Hpgd indeed has mainly extrinsic effects and 
does not affect the general phenotype or the transcriptional program of these cells. 
 
Figure 29: Co-transfer of Hpgd-deficient or competent Treg cells with WT Treg cells into Rag-
2-/- animals showed no intrinsic defects in Hpgd-deficient Treg cells 
A) Scheme of the experimental set-up. Hpgd-deficient or competent Treg cells were injected 
into Rag-2-/- animals with WT naïve T cells and WT Treg cells. Animals were sacrificed after 8 
weeks and Treg
 cells from mLN were analyzed. B) Weight curve of animals from (A) as an 
indication of colitis development. Recovered Treg cells from mLN as C) absolute number of 
YFP+ Treg cells and D) ratio of YFP
+ to RFP+ Treg cells. E) MA plot of gene expression of YFP
+ 
Hpgd-competent vs. Hpgd-deficient Treg cells isolated from (A). 
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4.3.6. Expression of Hpgd in Treg cells is important for metabolic homeostasis 
in aged mice 
Fat tissue is an important metabolic organ. Not only does it fulfill an important role in 
both lipid production and the regulation thereof (Summers, 2006) as well as in the metabolism 
of amino acids (Frayn et al., 1991), but it also fulfills important endocrine functions. Adipose 
tissue produces a variety of different hormones, cytokines and complement factors (Summers, 
2006). In response to these signals, immune cells in the VAT are activated, utilizing the 
adipose tissue as an important nutrient source, thus further increasing immune cell activation. 
Under obese conditions, immune cells in the VAT exhibit continuous low-grade activation, 
leading to systematic inflammation while during malnutrition immune cell activation is 
inhibited (Wensveen et al., 2015a). Thus, fat tissue plays a vital role in linking the metabolism 
with the immune system. Furthermore, fat tissue can be divided into two, functionally distinct 
subtypes: white adipose tissue (WAT), such as the VAT, which consists mainly of white 
adipocytes and confers largely negative effects on adiposity and insulin sensitivity, and brown 
adipose tissue (BAT), which consist mainly of brown adipocytes and has been shown to 
improve adiposity, insulin resistance and hyperlipidemia (Bartelt and Heeren, 2014). 
 
Figure 30: Metabolic parameters are worsened in aged animals with Hpgd-deficient Treg 
cells compared to WT littermate controls.  
Blood glucose levels after overnight fasting in A) aged and D) young animals with Hpgd-
deficient Treg cells or WT littermate controls. Insulin levels after overnight fasting in B) aged 
and E) young animals with Hpgd-deficient Treg cells or WT littermate controls. HOMA-IR of C) 
aged and F) young animals with Hpgd-deficient Treg cells or WT littermate controls. 
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Since a loss of Hpgd in Treg cells seems to lead to a dysregulation of immune cell 
populations in the VAT of aged animals resulting in local inflammation, we analyzed whether 
this perturbation of the immune cell compartment in the VAT also affects the metabolism of 
these animals. 
We performed all metabolic studies in male mice since it has been published that 
female mice are protected against metabolic syndrome under certain conditions (Pettersson et 
al., 2012), such as when challenged with HFD. Furthermore, we could not observe any 
differences in VAT-resident immune cell populations in female animals with Hpgd-deficient 
Treg cells (Figure 25). 
Since we could not observe a difference in bodyweight or VAT weight, but could 
detect a change in adipocyte size, we next analyzed the insulin signaling of aged animals with 
Hpgd-deficient Treg cells and their WT littermates. We measured the fasting glucose of these 
animals and could detect a significant increase in fasting glucose (Figure 30 A) and insulin 
levels after overnight fasting (Figure 30 B) in animals with Hpgd-deficient Treg cells. 
Therefore, these animals also had a higher Homeostatic Model Assessment for Insulin 
Resistance (HOMA-IR) score, a factor used to quantify insulin resistance, than the WT 
control animals (Figure 30 C). This seems indicative for the development of a metabolic 
dysregulation in aged animals when Hpgd is deleted in Treg cells. When analyzing these 
parameters in young animals, these differences could no longer be observed (Figure 30 D-F), 
showing that, like the expansion of Treg cells in the VAT, the metabolism of animals with a 
Treg cell specific Hpgd deletion is only disturbed in aged animals. To further confirm these 
observations, glucose and insulin tolerance tests were performed to assess the ability of the 
animals to appropriately react to the presence of glucose or insulin. For this, animals were 
fasted overnight or for four hours and then injected with glucose or insulin, respectively. To 
evaluate the metabolic state of these animals, blood glucose levels were measured at fixed 
intervals after injection. 
We could observe that aged animals with Hpgd-deficient Treg cells responded 
significantly less to both insulin (Figure 31 A) and glucose stimulation (Figure 31 B) than 
their WT counterparts. In young animals, however, no such difference could be measured 
(Figure 31 C and D), again indicating that the observed effect of Hpgd on the metabolism of 
the animals is age dependent. 
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Figure 31: The metabolism of aged animals with Hpgd-deficient Treg cells is less responsive 
to insulin and glucose.  
A) Insulin tolerance test of aged animals with WT or Hpgd-deficient Treg cells (left) and 
calculated AUC (right). B) Glucose tolerance test of aged animals with WT or Hpgd-deficient 
Treg cells (left) and calculated AUC (right). C) Insulin tolerance test of young animals with WT 
or Hpgd-deficient Treg cells (left) and calculated AUC (right). D) Glucose tolerance test of 
young animals with WT or Hpgd-deficient Treg cells (left) and calculated AUC (right).  AUC, 
area under the curve 
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Since we could observe a clear decrease in the response to insulin and glucose in old 
KO animals, we analyzed these animals in metabolic cages for 48 hours in collaboration with 
A. Pfeifer, University Hospital Bonn, to assess whether this is caused by alterations in their 
baseline activity, food intake or homeostatic metabolism. We could detect no difference in 
food intake (Figure 32 A), water intake (Figure 32 B), body composition (Figure 32 C) or 
motility (Figure 32 D). Furthermore, no difference in their respiration could be detected 
(Oxygen consumption, Figure 32 E, carbon dioxide consumption Figure 32 F, or respiratory 
exchange rate Figure 32 G), thus indicating that the animals show no difference in their 
homeostatic metabolism. 
 
Figure 32: No difference in the metabolism of aged mice with Hpgd-deficient or competent 
Treg cells could be detected under homeostatic conditions.  
Aged animals with Hpgd-deficient Treg cells and age-matched WT control animals were 
placed in metabolic cages and their A) food intake, B) water intake, C) body composition, D) 
motility, E) oxygen consumption, F) carbon dioxide consumption and G) respiratory 
exchange rate were recorded over a period of 48 hours. O2, oxygen; CO2, carbon dioxide; 
RER, respiratory exchange rate. Measurements performed by F. Copperi 
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Figure 33: pAKT signaling is reduced in the fat tissue of aged animals with Hpgd-deficient 
Treg cells. 
A) Immunoblot of liver, muscle, brown adipose tissue (BAT) and VAT of WT animals against 
pAKT (top) and AKT (bottom). Organs were harvested 3 min after i.p. injection of 0.5 U/kg 
bodyweight insulin or 200 µl PBS. pAKT to AKT ratio of aged animals with WT and Hpgd-
deficient Treg cells (after insulin challenge as described in A) from B) VAT, C) BAT, D) liver and 
E) skeletal muscle samples. pAKT, phosphorylated AKT. 
Subsequently, we analyzed the ratio of phosphorylated to unphosphorylated AKT in 
aged animals with Hpgd-deficient and Hpgd-competent Treg cells in the VAT, BAT, liver and 
skeletal muscle harvested three min after challenging the animals with 0.5 U/kg bodyweight 
of insulin. The ratio of pAKT/AKT after insulin challenge in animals with Hpgd-deficient Treg 
cells in the VAT and BAT is skewed towards AKT (Figure 33 B and C), indicating that 
insulin signaling in the fat tissue is reduced in these animals. Conversely, the pAKT/AKT 
ratio is skewed towards pAKT in both the liver and the skeletal muscle samples (Figure 33 D 
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and E), indicating that insulin signaling in these organs is increased, potentially due to a 
compensatory effect. 
In an effort to more closely analyze the effect of Hpgd-deficient Treg cells on insulin 
signaling in the VAT, we went further upstream in the insulin signaling cascade and 
investigated the mRNA expression of INSR1, IRS1 and IRS2 in the VAT of aged animals 
with Hpgd-deficient and competent Treg cells, sacrificed three min after insulin challenge. 
We could detect a significant decrease in mRNA levels of INSR1 in the VAT of aged 
animals with Hpgd-deficient Treg cells compared to age-matched WT control animals (Figure 
34). However, we could not detect a difference in either IRS1 or IRS2 mRNA expression in 
these samples (Figure 34), suggesting that the decrease in insulin signaling might be caused 
by a downregulation of the receptor INSR1. 
 
Figure 34: INSR1 mRNA is expressed at lower levels in VAT of aged animals with Hpgd-
deficient Treg cells after insulin challenge.  
Aged animals were challenged with 0.5 U/ml insulin for three min prior to sacrifice. VAT was 
excised and mRNA was isolated from the whole organ and mRNA expression of the insulin 
receptor 1 (INSR1) and of the insulin receptor substrates (IRS) 1 and 2 was determined. 
Mean expression of WT animals was normalized to 1. 
To analyze the composition and functionality of the VAT and BAT of aged animals 
with Hpgd-deficient Treg cells, we performed protein analysis by immunoblotting. 
As expected, we could not detect any uncoupling protein 1 (Ucp1), a marker for brown 
adipocytes, in the VAT (Figure 35 A). However, we could observe a significant increase in 
Ap2 in VAT of mice with KO Treg cells (Figure 35 A, quantified in Figure 35 B). Ap2 is a 
fatty acid binding protein directly downstream of Ppar-γ, whose deletion has been implicated 
in the improvement of multiple different pathologies associated with the development of a 
metabolic syndrome. Similarly, deletion of Ap2 leads to protection against obesity, 
(Hotamisligil et al., 1996; Uysal et al., 2000), improved insulin signaling (Maeda et al., 2005) 
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and protection against atherosclerosis (Boord et al., 2002; Makowski et al., 2001). 
Furthermore, it has been suggested that inhibiting Ap2 might be a treatment option for 
different metabolic diseases (Furuhashi et al., 2007). Thus, the observed upregulation of Ap2 
in VAT is further indicative of a worsened metabolic state in aged animals with Hpgd-
deficient Treg cells.  
Meanwhile, in the BAT we could observe a downregulation of Ap2 in aged animals 
with Hpgd-deficient Treg cells compared to age-matched littermate control animals (Figure 35 
C, quantified in Figure 35 D). This might suggest a compensatory effect in the BAT. 
Furthermore, we could not detect a difference in Ucp1 expression between aged animals with 
Hpgd-competent and deficient-Treg cells (Figure 35 C, quantified in Figure 35 E), suggesting 
that the functionality of the BAT is not negatively influenced by a lack of Hpgd in Treg cells. 
 
Figure 35: Ap2 is upregulated in VAT of aged animals with Hpgd-deficient Treg cells 
compared to WT control animals.  
Immunoblot of A) VAT and C) BAT of aged animals with Hpgd-deficient or competent Treg 
cells of Ap2, Ucp1 and Calnexin. Quantification of Ap2 in B) VAT and D) BAT and E) Ucp1 in 
BAT. Ucp1, uncoupling protein 1 
It has been previously described that metabolic dysregulation and the VAT-resident 
immune cell population are linked (Andersen et al., 2016). Besides alterations in the myeloid 
cell compartment, it has also been described that natural killer (NK) cell numbers are 
increased in high fat diet (HFD) models. This increase in NK cell numbers goes hand in hand 
with an increase in insulin resistance (Lee et al., 2016). Additionally, it has been shown that 
obesity leads to the upregulation of receptors on adipocytes which activate NK cells on 
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adipocytes, thus resulting in the production of pro-inflammatory cytokines by NK cells. These 
cytokines consequently lead to the recruitment and polarization towards a more pro-
inflammatory state of macrophages in the VAT (Wensveen et al., 2015b). Since we observed 
an increase in the Treg cell and proinflammatory macrophage compartments in animals with a 
Treg cell specific deletion of Hpgd in aged animals (see chapter 4.3.3), we analyzed the NK-
cell population in the VAT of these animals.  
In accordance with these published data, we could observe an increase in the NK cell 
population in the VAT of aged animals with Hpgd-deficient Treg cells compared to WT 
littermate controls (Figure 36 A). However, we could not detect a difference in the NKT-cell 
population of VAT in these animals (Figure 36 C) or a difference in the NK or NKT-cell 
population in the spleen (Figure 36 B and D). These observations, linked with the increased 
infiltration of pro-inflammatory macrophages and decreased Ap2 levels in the VAT as well as 
decreased insulin sensitivity in aged animals with Hpgd-deficient Treg cells, are similar to 
previously published data of animals fed a HFD and might indicate that Hpgd in Treg cells 
plays a role in obesity. 
 
Figure 36: Aged animals with Hpgd-deficient Treg cells have an increased NK-cell 
population in the VAT. 
Absolute A) NK and B) NKT cell numbers in WT animals and animals with Hpgd-deficient Treg 
cells isolated from the VAT. Absolute C) NK and D) NKT cell numbers in WT animals and 
animals with Hpgd-deficient Treg cells isolated from the spleen. 
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4.3.7. Loss of Hpgd in Treg cells leads to reduced insulin sensitivity during high 
fat diet 
Since we could show that a Treg cell specific deletion of Hpgd affects both the immune 
homeostasis of the VAT as well as the metabolism of aged animals, we attempted to 
exacerbate the observed effects by challenging these animals by inducing obesity. To this end, 
we subjected young animals to HFD for 15 weeks. However, even though the animals gained 
significantly more weight than the littermate control animals on normal diet (ND) (Figure 37 
A), there was no significant difference in the weight between animals with Hpgd-deficient 
Treg cells and WT littermate controls after 15 weeks of HFD feeding (Figure 37 A and B). 
 
Figure 37: No difference in weight gain between animals with Hpgd-deficient Treg cells and 
WT littermate control animals after 15 weeks of HFD.  
A) Weight curve of animals with Hpgd-deficient or WT Treg cells after 15 weeks on HFD or 
ND. B) Final weight of animals with Hpgd-deficient Treg cells after 15 weeks on HFD and of 
WT littermate control animals. HFD, high fat diet; ND normal diet. 
After fasting these animals for 16 hours and measuring fasting glucose levels, we could 
not detect a difference between the animals with Hpgd-deficient and Hpgd-competent Treg 
cells, either on ND or on HFD (Figure 38 A). However, we could detect a clear increase in 
fasting glucose between animals subjected to ND vs. HFD diet. This, in conjunction with the 
decrease in insulin sensitivity in HFD-fed animals (Figure 38 B and C), demonstrated that the 
induction of obesity successfully reduced the metabolic responsiveness of these animals. 
When comparing the effect of insulin on animals with a Treg cell specific deletion of Hpgd 
to WT littermate controls after 15 weeks of HFD, we could observe that the animals with 
deficient Treg cells respond less (Figure 38 B and C), resembling what we observed previously 
with aged animals under homeostatic conditions (Figure 31 A). However, the difference in 
insulin sensitivity in these obese animals is not as pronounced as in the aged animals. 
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Figure 38: Animals with Hpgd-deficient Treg cells show reduced insulin sensitivity after 15 
weeks of HFD feeding.  
A) Blood glucose levels after overnight fasting of animals with Hpgd-deficient or WT Treg cells 
after 15 weeks on HFD or ND. B) Insulin tolerance test and C) corresponding AUC of animals 
with Hpgd-deficient or WT Treg cells 15 weeks on HFD or ND.  
 Subsequently, we analyzed the VAT of these animals and could observe that the VAT of 
animals with Hpgd-deficient Treg cells weighed less than that of WT littermate control animals 
after 15 weeks of HFD feeding (Figure 39 A). Further, similar to our observations in aged 
animals, we could detect an increase in the number of Treg cells per gram VAT in these 
animals (Figure 39 B). However, we could not detect a difference in the percentage or the 
absolute size of the population (data not shown), indicating that the observed difference in 
Treg cells may be caused by the decreased amount of VAT in the animals with Hpgd-deficient 
Treg cells. 
In addition, unlike in aged animals, we could not detect an increase in the macrophage 
population in the VAT of animals with Hpgd-deficient Treg cells compared to WT littermate 
control animals after 15 weeks of HFD feeding (Figure 39 C). 
Thus, subjecting animals to HFD does not seem to completely recapitulate the 
phenotype observed in aged animals – apart from a slight decrease in insulin sensitivity in 
animals with Hpgd-deficient Treg cells compared to WT littermate control animals on HFD 
diet. This indicates that the HFD model is not the optimal model to study the effect of a Treg 
cell specific loss of Hpgd, possibly due to the obesity caused increase of basal inflammation 
which no longer enables us to detect the increase in inflammation in the KO animals in 
comparison to WT animals. 
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Figure 39: Analysis of VAT of animals with Hpgd-deficient or Hpgd-competent Treg cells 
after 15 weeks of HFD.  
A) Weight of VAT of animals with Hpgd-deficient Treg cells and WT littermate control animals 
after 15 weeks of HFD. B) Treg and C) F4/80
+ Macrophage population of the VAT of animals 
with and without Hpgd-deficient Treg cells after 15 weeks of HFD feeding in cells/g VAT. 
 
4.4. HPGD in human T2D 
Controlling inflammation is crucial for limiting T2D pathogenesis, as increased levels 
of pro-inflammatory cytokines have been linked to decreased insulin sensitivity and several of 
the secondary associated effect (Bruun et al., 2003). Furthermore, Treg cells have been shown 
to be vital in suppressing inflammation at primary and secondary sites of T2D pathogenesis, 
including in VAT and the kidneys (Eller et al., 2011; Kornete et al., 2013). Thus, a correlation 
between T2D and Treg cell functionality exists. Since the phenotype we observed in aged 
animals with KO Treg cells is reminiscent of non-obese T2D, i.e. no significant weight gain 
coupled with a dysregulation of the immune cell population in the fat tissue and decreased 
insulin sensitivity, we analyzed PB of lean T2D patients compared to healthy control patients. 
Thus, we applied linear support vector regression (SVR), which infers the contribution of 
various gene expression signatures in one dataset to a publicly available microarray dataset. 
This allowed us to estimate the distribution of different immune cell populations in the 
cohort (Newman et al., 2015). When analyzing these data, we could observe a significant 
change in the makeup of the leukocyte population of PB samples isolated from T2D patients 
compared to healthy controls (Figure 40 A). The granulocyte and monocyte population of 
T2D patients is expanded, reminiscent of the increase of the myeloid population in the VAT 
of aged animals with a Treg cell specific deletion of Hpgd. When further analyzing the Treg 
cells of this dataset, we could detect a significant decrease in the frequency of Treg cells in the 
PB of T2D patients compared to healthy individuals (Figure 40 B). 
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Figure 40: Human T2D patients have a smaller Treg cell fraction compared to healthy 
individuals.  
A) Relative quantification of leukocyte populations of microarray data of PB isolated 
from healthy controls and patients with type II diabetes (T2D) as determined by linear 
support vector regression. B) Relative quantification of Treg cells in microarray samples of 
PB of T2D patients and healthy controls as determined by linear support vector 
regression. Analysis performed by K. Baßler. 
 
In a separate microarray dataset, consisting of Treg and Tconv cells isolated from the PB 
of T2D patients and healthy individuals, we more closely analyzed gene expression in Treg 
cells of T2D patients. We could not detect a difference in FOXP3 levels between Treg cells 
isolated from healthy individuals and T2D patients (Figure 41 A). 
In a subsequent step, we analyzed HPGD expression levels in this dataset. As 
expected, the level of HPGD expression is significantly higher in Treg cells than in Tconv cells, 
both in T2D and in healthy control samples. However, the observed increase in HPGD levels 
is significantly lower in T2D patients than in healthy individuals (Figure 41 B).  
To confirm these bioinformatic analyses with our own experimental data, we sorted 
CD3
+
CD4
+
CD25
+
CD127
-
 Treg and CD3
+
CD4
+
CD25
-
CD127
+
 Tconv cells from PB of T2D 
patients and healthy, age-matched individuals and analyzed both FOXP3 and HPGD 
expression. Using qRT-PCR, we could confirm that, as anticipated, the Treg cells of both 
healthy and T2D patients express significantly more FOXP3 than the Tconv cells, with no 
detectable difference between T2D and healthy control Treg cells (Figure 42 A).  
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Figure 41: T2D patients express significantly lower amounts of HPGD in PB Treg cells than 
healthy individuals.  
Relative A) FOXP3 and B) HPGD mRNA levels of Treg and Tconv cells isolated from the pB of 
T2D patients and healthy controls. 
When analyzing HPGD expression in these cells, we could detect a significant 
increase in both T2D and healthy control Treg cells compared to Tconv cells. Additionally, as 
observed in the microarray dataset, we could measure a significant decrease in HPGD 
expression in Treg cells of T2D patient samples compared to healthy control Treg cells (Figure 
42 B). Thus our data confirm the microarray data analysis. 
 
Figure 42: T2D patients exhibit significantly lower HPGD in Treg cells isolated from PB than 
healthy individuals.  
Relative A) FOXP3 and B) HPGD levels of Treg and Tconv cells isolated from the PB of T2D 
patients and healthy individuals. Expression of Tconv cells was normalized to 1. 
Furthermore, when analyzing the PB Treg cell population in T2D patients compared to 
healthy individuals, we could detect a significant increase in the relative size of the population 
in T2D patients (Figure 43 A and B), however, this increase was based on a shift of the 
Treg/Tconv ratio in these T2D patients. This increase is reminiscent of the increase in the Treg 
cell population of the VAT of aged animals with Hpgd-deficient Treg cells (Figure 19 B and 
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C). Taken together, these data seem to indicate that HPGD expression in Treg cells might play 
a role in human T2D. However, it remains unclear whether a decrease of HPGD-levels and 
the accompanying decrease in Treg cell functionality is a cause or an effect of T2D. 
All in all, in this work we could show that Hpgd is an important mediator of both 
human and murine Treg cell suppression through the metabolism of PGE2 into 15-keto-PGE2 
in an at least partially Ppar-γ-dependent manner. A Treg cell specific loss of Hpgd led to a 
decrease in suppression in PGE2-rich environment accompanied by an increase in the VAT-
resident Treg and proinflammatory macrophage population coupled with a decrease in 
metabolic function. Further, we could correlate decreased HPGD levels in human Treg cells to 
T2D.  
4.5. MEOX1 is upregulated in human Treg cells 
To further analyze the regulation of gene expression in Treg cells and identify key 
components of the Treg cell transcriptome, an extensive bioinformatic analysis of different Treg 
and Tconv cell populations was performed by K. Baßler during his master thesis. This led to the 
identification of the transcription factor MEOX1 as highly upregulated in stimulated human 
Treg cells. When analyzing the expression of MEOX1 and FOXP3 in the previously published 
microarray dataset used to identify HPGD as key Treg cell molecule (Beyer et al., 2011), 
MEOX1 was found to be upregulated in most Treg cell conditions, and most highly 
upregulated in conditions 27 and 28, the two conditions in which Treg cells were activated 
with CD3 and IL-2 (Figure 44 B) whilst FOXP3 was upregulated across all Treg cell 
conditions (Figure 44 A). 
 
Figure 43: T2D patients exhibit a significantly higher Treg cell population than healthy age 
matched individuals. 
Cells were isolated from PB of T2D patients and age-matched healthy controls and stained 
for protein measurements. A) Representative plots and B) quantification. 
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Figure 44: MEOX1 is upregulated in human Treg cells.  
A) FOXP3 and B) MEOX1 mRNA levels in CD4+ Tconv and Treg cells under different stimulation 
conditions (available under GEO accession number GSE15390). Analysis performed by K. 
Baßler. 
To validate the bioinformatics analyses, Treg and Tconv cells were sorted from human 
blood and MEOX1 mRNA expression was analyzed. As expected, we could detect 
significantly elevated FOXP3 levels in Treg cells compared to Tconv cells (Figure 45 A). 
Moreover, we could also detect increased MEOX1 levels in these cells (Figure 45 B). This 
increase in MEOX1 expression could be increased by stimulating the cells overnight with IL-
2 (Figure 45 C), thus further confirming the results of the microarray analysis (Figure 44B). 
 
Figure 45: MEOX1 is upregulated in human Treg cells.  
A) FOXP3 and B) MEOX1 mRNA expression of sorted human Treg and Tconv cells. C) Sorted 
human Treg cells were cultivated overnight either with or without 100 U IL-2 per ml and 
MEOX1 mRNA expression was measured by qRT-PCR. Mean expression of Tconv cells (panel A 
and B) or unstimulated Treg cells (panel C) was normalized to 1. 
 
In an effort to further explore the role of IL-2 for MEOX1 expression, Treg cells were 
isolated by positive magnetic bead sorting and stimulated with different levels of IL-2, 
ranging from 10 U/ml (Figure 46 A) and 100 U/ml (Figure 46 B) to 1000 U/ml (Figure 46 C) 
and MEOX1 levels were determined at defined intervals between 12 and 72 hours after 
stimulation.  
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Figure 46: MEOX1 expression is upregulated in human Treg cells in the presence of IL-2.  
Human Treg cells were cultivated in the presence of A) 10 B) 100 and C) 1000 U/mL IL-2 for 
72 hours and MEOX1 mRNA levels were determined before stimulation and 12, 24, 48 and 
72 hours after stimulation. As control, unstimulated Treg cells were used. MEOX1 expression 
at 0 hrs was normalized to 1. 
Already after 12 hours, we could observe a more than 10-fold increase in MEOX1 
levels which then continuously decreased again until after 72 hours of stimulation MEOX1 
levels returned to unstimulated levels. This increase was dose-independent as there seems to 
be no difference between stimulating with 10, 100 or 1,000 U/ml of IL-2 (Figure 46 A-C). 
 
Figure 47: Transfection of a MEOX1 expression plasmid into HEK293T cells.  
A) Construct used for transfection into HEK293T cells. eGFP linked with a 2A peptide to 
MEOX1 under the control of the constitutive EF1-α promoter in a pENTR4 backbone. B) 
Transfection efficacies of HEK293T cells with an empty pENTR4 plasmid (left) and the 
pENTR4-eGFP-2A-MEOX1 construct (right). 
In a subsequent step, the protein expression of MEOX1 in human Treg and Tconv cells 
was examined. Due to the limited availability of human Treg cell protein samples, the WES 
system, a capillary system with a theoretical detection limit of 0.3 µg of protein was used. To 
test the WES system and the MEOX1 antibodies, a positive control for protein analyses was 
generated by transfecting a plasmid containing MEOX1 under the control of an EF1-α 
promoter, a constitutive promoter of human origin (Figure 47 A) into HEK293T cells. Only 
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samples with transfection efficiencies of 70% or higher were used for subsequent protein 
analysis (Figure 47 B). 
When applying protein lysates of HEK293T cells and HEK293T cells containing the 
MEOX1 overexpression plasmid to a traditional immunoblot, a specific band of 
approximately 36 kDa was detected only in the sample overexpressing MEOX1 (Figure 48 
A), even though MEOX1 is predicted to run at 28 kDa. However, since MEOX1 expression 
was artificially induced in HEK293T cells by transfection and could not be detected in normal 
HEK cell lysates, we conclude that this is the specific MEOX1 band, running slightly higher 
due to possible posttranslational modifications. When applying these samples to the more 
sensitive WES system, we could detect a peak at 38 kDa in the samples overexpressing 
MEOX1 but not in the HEK293T cell protein lysate (Figure 48 B). Due to the similar size and 
expression, we assume that this is the same peak that we already observed on the traditional 
immunoblot. 
 
Figure 48: MEOX1 is upregulated on protein level in stimulated human Treg cells compared 
to Tconv cells.  
A) Traditional western and B) WES of HEK cells and HEK cells overexpressing MEOX1. C) WES 
of human Tconv cells and Treg cells stimulated overnight with 100 U/mL IL-2. D) Representative 
(left) and cumulative (right) flow cytometric analysis of MEOX-1 expression in IL-2 stimulated 
Treg and Tconv cells. OE, overexpression 
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After confirming that the antibody is capable of specifically detecting MEOX1 using 
the WES system, we then compared the MEOX1 expression between sorted human Tconv and 
Treg cells after stimulating the cells with 100 U/ml IL-2 for 16 hours and could detect a peak at 
39 kDa in the Treg cell lysate but not in the Tconv cell sample (Figure 48 B). We could confirm 
these data in flow cytometric analyses, where we could show that MEOX1 is expressed at 
significantly higher levels in IL-2 stimulated Treg cells compared to IL-2 stimulated Tconv cells 
(Figure 48 D). Thus, we could clearly show that MEOX1 is present not only on mRNA but 
also on protein level in Treg cells but not in Tconv cells after IL-2 stimulation. 
4.5.1. MEOX1 is regulated by FOXP3 but does not control the expression of 
HPGD 
Next, we were interested in the mechanisms through which expression of MEOX1 is 
regulated. As E. Schönfeld could show in her PhD thesis that HPGD, similar to MEOX1, is 
also upregulated after IL-2 stimulation (Schönfeld, 2011), we decided to more closely analyze 
whether there might be a connection between the regulation of MEOX1 and HPGD. 
K. Baßler found that HPGD and MEOX1 both appear in the same WGCNA module, 
thus indicating that a similar mechanism of gene expression is likely. We hypothesized that 
the most likely common mechanism of regulation is by the Treg cell defining transcription 
factor FOXP3, which we have previously shown binds to the HPGD locus and governs 
HPGD expression (data not shown). Indeed, when K. Baßler perfomed a binding motive 
analysis of Treg cells stimulated with IL-2 using iRegulon, he found that MEOX1 contains a 
FOXP3 binding site. This implies that MEOX1 expression might be regulated by FOXP3 
binding. Therefore, we analyzed the effect of silencing FOXP3 in human Treg cells by 
introducing small, interfering RNAs (siRNAs) against FOXP3 and subsequently analyzing 
MEOX1 expression. 
In order to confirm the knockdown efficiency, we analyzed FOXP3 expression and 
could detect a decrease in FOXP3 expression of more than 50% in cells transfected with 
FOXP3 siRNAs compared to control cells transfected with scrambled siRNAs (Figure 49 A). 
When analyzing MEOX1 expression in these cells, we could detect a significant 
decrease in MEOX1 expression in cells transfected with siRNAs specific for FOXP3 
compared to the control cells. This indicates that FOXP3 is upstream of MEOX1 and that the 
presence of FOXP3 promotes the expression of MEOX1 (Figure 49 B). 
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Figure 49: A knockdown of FOXP3 in human Treg cells leads to a reduction of MEOX1 
expression  
Relative A) MEOX1 and B) FOXP3 levels in human Treg cells, 48 hours after transfection with 
either scrambled or FOXP3 siRNA. Expression levels of cells transfected with scrambled 
siRNAs were normalized to 1. 
To analyze whether the regulation of MEOX1 by FOXP3 is reciprocal, we performed 
MEOX1 siRNA knockdowns in human Treg cells and analyzed FOXP3 and HPGD mRNA 
levels. While the knockdown efficiency of the MEOX1 siRNAs was not as high as that of the 
FOXP3 siRNAs, we could still detect a significant decrease in MEOX1 levels of nearly 50% 
in cells transfected with MEOX1 siRNA compared to cells transfected with scrambled 
siRNAs as a control (Figure 50 A). However, we could not detect a difference in either 
FOXP3 (Figure 50 B) or HPGD (Figure 50 C) expression in response to the MEOX1 
knockdown. Thus, we conclude that the transcription factor MEOX1, while downstream of 
the Treg cell lineage defining transcription factor FOXP3, does not play a role in the regulation 
of either HPGD or FOXP3 expression. 
 
Figure 50: Silencing of MEOX1 in human Treg cells does not affect either FOXP3 or HPGD 
expression. 
Relative A) MEOX1 B) FOXP3 and C) HPGD levels in human Treg cells, 48 hours after 
transfection with either scrambled or MEOX1 siRNA. Expression levels of cells transfected 
with scrambled siRNAs were normalized to 1. 
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All in all, these results indicate that HPGD, through the metabolism of PGE2 into 15-
keto-PGE2, is an important mediator of Treg cell mediated Tconv cell suppression, both in the 
murine system and in humans, in an, at least partially, Ppar-γ-dependent manner. We could 
further observe a dysregulation of the metabolism when Treg cells lack Hpgd in aged mice and 
a downregulation of HPGD in human T2D, indicating that the expression of HPGD plays an 
important role in the function of Treg cells crucial to maintain metabolic homeostasis. 
When analyzing the role of the transcription factor MEOX1 in Treg cell biology, we 
could show that MEOX1 is highly upregulated in Treg cells, especially after IL-2 stimulation. 
Furthermore, we could demonstrate that MEOX1 is downstream of FOXP3. However, we 
could not detect a correlation between HPGD and MEOX1 expression. 
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5. Discussion 
Following immune cell activation, the immune response needs to be modulated to 
avoid a chronic proinflammatory state and autoimmunity. Here, Treg cells play an important 
role. However, despite being one of the main mediators of immunoregulation, the exact 
functionality of Treg cells is poorly understood, especially in a tissue context specific manner. 
It has been long accepted that the Treg cell population is diverse and can be classified 
in a variety of different manners: depending on their tissue of origin either as thymic or 
peripheral Treg cells or depending on their state of activity as naive or effector Treg cells. More 
recently, however, Treg cells have been classified based on their tissue of residence (Burzyn et 
al., 2013; Kolodin et al., 2015). For instance, it has been described that the transcriptional 
signature of VAT-resident Treg cells varies significantly from that of lymphoid Treg cells, 
differing in the expression of chemokine receptors, cytokines, metabolic proteins as well as in 
their TCR repertoire (Feuerer et al., 2009). 
We performed a more detailed analysis of human Treg cells and found that the PGE2 
metabolizing enzyme HPGD is upregulated in human Treg cells in general, but also in murine 
Treg cells. This upregulation is especially prominent in the VAT, a PGE2-rich environment. 
Correspondingly, we hypothesized that HPGD might play a role in Treg cell functionality, 
especially in VAT-resident Treg cells. 
Indeed, we could show that the 15-keto-PGE2, a direct, Hpgd-dependent metabolite of 
PGE2, is an important mediator of Tconv cell suppression. Furthermore, we could show that 
Treg cell expression of Hpgd is important for VAT immune-homeostasis and is vital to 
maintain a healthy metabolism; a finding which we could recapitulate in animals subjected to 
a HFD, where animals with Hpgd-deficient Treg cells showed reduced insulin sensitivity. 
Furthermore, we could show that in the PB of human T2D patients HPGD expression is 
significantly reduced in comparison to healthy age-matched individuals. 
Finally, we analyzed whether the transcription factor MEOX1 plays a role in 
controlling HPGD expression and could show that while MEOX1, like HPGD, is regulated by 
FOXP3, the Treg cell lineage defining transcription factor, we could not detect an influence of 
MEOX1 expression on HPGD. 
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5.1. Suppressive role of the HPGD-mediated PGE2 metabolite 15-keto-PGE2 via 
PPAR-γ-signaling 
In a large transcriptome analysis, we could show that HPGD is significantly 
upregulated across all Treg cell conditions we analyzed. Initially, the upregulation of the PGE2 
metabolizing enzyme HPGD in Treg cells seems counterintuitive since it has been previously 
published that PGE2 leads to the upregulation of the lineage defining transcription factor 
FOXP3 in Treg cells and that the presence of PGE2 leads to an increase in the suppressive 
functionality of Treg cells (Baratelli et al., 2005). We could confirm these observations in 
suppression assays conducted in the presence of PGE2. However, while it was previously 
proposed that PGE2 acts a) directly on Tconv cells to exert its suppressive function (Chemnitz 
et al., 2006) and b) increases Treg cell functionality by augmenting FOXP3 expression and 
thereby Treg cell identity (Baratelli et al., 2005), we could show that this might not be the main 
mechanism of action as in the absence of Treg cells, PGE2 did not affect Tconv cell proliferation 
while the Hpgd-mediated metabolite 15-keto-PGE2 exhibited suppressive functionality 
independently of Treg cells. Furthermore, a loss of Hpgd in Treg cells also abrogated that 
suppressive capacity of PGE2, both in in vitro suppression assays and in in vivo colitis 
experiments. Thus, we were able to confirm the previously published observation that PGE2 is 
beneficial for the suppressive capacity of Treg cells and hypothesize that the mechanism in 
which this suppression occurs is via the HPGD dependent metabolism of PGE2 into 15-keto-
PGE2. 
A 15-keto-PGE2 mediated suppressive effect has been previously observed, albeit not 
in the context of T-cell biology. It is particularly well characterized in cancer progression, 
where 15-keto-PGE2 has been shown to inhibit the proliferation of pancreatic adenocarcinoma 
and hepatocellular carcinoma (Chang et al., 2016; Lu et al., 2014). However, the exact 
mechanism of 15-keto-PGE2-mediated inhibition of cell proliferation is unclear, even though 
it has been suggested, at least in hepatocellular carcinoma, that the observed suppressive 
effect is mediated by Ppar-γ signaling (Lu et al., 2014).  
15-keto-PGE2 has been shown to be a ligand of Ppar-γ (Chou et al., 2007), an 
observation which we could corroborate as the effect of 15-keto-PGE2 closely mirrors that of 
the known Ppar-γ ligand Rosiglitazone. Furthermore, when we analyzed the suppressive 
effect of 15-keto-PGE2 on the proliferation of Ppar-γ-deficient Tconv cells, we could detect a 
significant decrease in 15-keto-PGE2 dependent suppression of proliferation. Thus, Hpgd 
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seems to induce Ppar-γ signaling through the metabolism of PGE2 into the Ppar-γ ligand 15-
keto-PGE2. 
 Ppar-γ signaling has long since been ascribed an immunomodulatory role. For 
instance, in monocytes an induction of Ppar-γ leads to a downregulation of different 
proinflammatory cytokines and chemokines (Dasu et al., 2009; Dinarello, 2010). Furthermore, 
Ppar-γ activation in macrophages leads to inhibition of proliferation and polarization towards 
an anti-inflammatory phenotype (Bouhlel et al., 2007; Lin et al., 2014) while in B cells, an 
activation of the Ppar-γ signaling pathway induces cell death (Padilla et al., 2002). In 
addition, the activation of Ppar-γ signaling leads to an expansion of VAT-resident Treg cells 
and a decrease in VAT inflammation (Cipolletta et al., 2012). All in all, this shows that Ppar-γ 
signaling plays an important immunomodulatory role and indicates that activation of Ppar-γ 
signaling in Tconv cells leads to decreased cell proliferation, thus hampering the immune 
response and leading to a more immunomodulated environment. 
Conversely, deleting Ppar-γ leads to the downregulation of Hpgd in lymphatic Treg 
cells and especially in VAT-resident Treg cells. This indicates that Ppar-γ is not only 
downstream but also upstream of Hpgd and that the transcription factor is required for the 
expression of Hpgd. However, how Ppar-γ influences Hpgd is largely unknown. We would 
hypothesize that the effect is caused by instructional events which determine the Treg cell fate. 
However, where these signals originate is uncertain, but we believe that these signals are 
derived from the adipose tissue rather than from Tconv cells.  
However, HPGD expression is not limited to Treg cells. Rather, a variety of different 
myeloid cells, such as DCs and macrophages, also express HPGD at relatively high levels. 
Therefore, it could be argued that these cells may also be involved in the regulation of Tconv 
cell proliferation by affecting the 15-keto-PGE2 levels in their environment. However, when 
we analyzed the expression level of PTGR1 and PTGR2, the two major enzymes involved in 
the further metabolism of 15-keto-PGE2, we could show that while the enzymes are highly 
expressed in myeloid cells, the expression is largely absent in T cells. This indicates that in 
myeloid cells 15-keto-PGE2 is further metabolized into 13,14-dihydro-15-keto-PGE2, which is 
highly unstable under homeostatic conditions and therefore rapidly degraded (Fitzpatrick et 
al., 1980). Furthermore, it has been previously described that inhibiting PTGR2 and thus the 
degradation of 15-keto-PGE2 in pancreatic cancer leads to suppressed cell proliferation and 
increased apoptosis in the pancreas (Chang et al., 2016), thus indicating that 15-keto-PGE2, 
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but not the direct metabolite 13,14-dihydro-15-keto-PGE2, has a suppressive effect on the 
proliferation of surrounding cells. Taken together, this indicates that, while it is of course 
possible that myeloid cells play a role in fine-tuning PGE2 concentrations, Treg cells seem to 
be the most important players in controlling local 15-keto-PGE2 concentrations, thereby 
influencing Tconv cell activation and proliferation.  
5.2. Role of Hpgd in VAT Treg cells of aged animals 
Subsequently, we analyzed the role of Hpgd in Treg cells of the VAT, as the VAT is an 
organ rich in PGE2. We found that Hpgd is significantly upregulated in Treg cells of the VAT, 
both in comparison to Tconv cells and to other tissue resident Treg cells. Thus, it might be 
interesting to analyze other PGE2-rich tissues, such as the brain or tumor tissues. However, re-
analysis of previously published datasets showed no differences in Hpgd expression either in 
human or murine tumor tissue Treg cells compared to healthy tissues. When analyzing Treg 
cells from the brain, we could not isolate a sufficient number to analyze Hpgd expression in 
Treg cells under homeostatic conditions. Nevertheless, it might be interesting to analyze Hpgd 
expression in CNS-resident and infiltrating Treg cells after e.g. EAE induction or viral 
challenges. 
Treg cells can be further classified into effector and naïve Treg cells. Recently, effector 
Treg cells have been implicated in tissue residency and in the maintenance of tissue 
homeostasis (Sharma and Rudra, 2018). Tissue-resident Treg cells have been shown to further 
differentiate into effector Treg cells by upregulating critical genes of the Treg cell signature 
(Dias et al., 2017). Even though we did not analyze the expression level of effector Treg cell 
markers in Hpgd-expressing VAT-resident Treg cells, we postulate that the upregulation of 
Hpgd in VAT-resident Treg cells occurs during the differentiation into tissue-resident effector 
Treg cells. These Hpgd expressing Treg cells make up a specific effector population, which 
probably originate from the spleen since recent findings show that a subpopulation of splenic 
Treg cells already expresses Ppar-γ and functions as a precursor for VAT-resident effector Treg 
cells (Li et al., 2018). 
When analyzing the VAT of aged animals with Hpgd-deficient Treg cells, we observed 
a significant increase in the VAT-resident Treg cell population. We hypothesize that this 
increase is a compensatory effect to negate the loss of function caused by the deletion of 
Hpgd in Treg cells. In line with this hypothesis, we could also detect an increase in the 
proinflammatory macrophage and NK-cell populations, while the corresponding populations 
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in the spleen remain unaltered. These observations are very similar to what one would expect 
in an animal subjected to HFD: an increase in inflammation and a deregulation of the 
immune-cell population in the VAT, such as an increase in NK cells (Lee et al., 2016; 
Wensveen et al., 2015b). Furthermore, this increase in macrophages has also been described 
in ob/ob mice, which serve as a model for T2D. In ob/ob mice, this increase could be reversed 
by expanding the Treg cell population in the VAT by administering both anti‐CD3 and β‐
glucosylceramide (Ilan et al., 2010). Moreover, increasing the VAT-resident Treg cells also 
improved different metabolic parameters (Feuerer et al., 2009; Ilan et al., 2010). Conversely, a 
loss of VAT-resident Treg cells has been previously shown to negatively impact different 
metabolic parameters, for instance fasting glucose levels and insulin sensitivity (Becker et al., 
2017; Eller et al., 2011; Feuerer et al., 2009). 
Thus, VAT-resident Treg cells have been implicated in metabolic signaling. Our own 
findings were able to further validate the metabolic role of Treg cells as a deletion of Hpgd and 
the consequent accumulation of non-functional Treg cells in the VAT leads to worsened 
metabolic parameters, decreased insulin and glucose sensitivity as well as decreased insulin 
signaling and a decrease in the expression of INSR1 in aged animals. This spontaneous 
development of a metabolic syndrome can be explained by the increased accumulation of 
PGE2, an important factor contributing to VAT homeostasis (García-Alonso et al., 2016). 
Normally, the Hpgd-expressing VAT-resident Treg cell population metabolizes PGE2 into the 
suppressive Ppar-γ ligand 15-keto-PGE2 thus preventing adipose tissue inflammation. 
However, in the absence of a functional Treg cell population, PGE2 accumulation leads to 
increased inflammation and a dysregulation of the metabolism in these animals, thus further 
confirming the importance of Hpgd for the functionality of VAT-resident Treg cells, as the 
deletion of the enzyme mirrors the effects of depleting Treg cells from the VAT (Cipolletta et 
al., 2012). 
Interestingly, while we could observe the spontaneous development of a metabolic 
syndrome in animals with Hpgd-deficient Treg cells, resulting in a reduced insulin and glucose 
sensitivity, we could observe an increase in pAKT/AKT ratio in the liver and in muscle tissue 
of these animals in comparison to littermate control animals, indicating increased insulin 
signaling in these organs. Meanwhile, in the VAT and BAT of these animals we could 
observe a decrease in pAKT/AKT ratio, in line with the spontaneous development of a 
metabolic syndrome. These data are slightly incongruous as in the classical development of a 
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human metabolic syndrome, decreased muscle tissue insulin sensitivity has been shown to be 
one of the first detectable metabolic pathologies of the disease (Rabøl et al., 2011; Zhang and 
Liu, 2014). Thus, either the evolution of the metabolic syndrome in these animals differs from 
the development of T2D or the improved insulin signaling in muscle and liver are indicative 
of a compensatory mechanism. 
5.3. Role of Hpgd in VAT Treg cells in HFD challenged animals 
In an attempt to challenge the metabolic state of these animals and to analyze the role 
of Hpgd in Treg cells under non-homeostatic conditions, we subjected animals with Hpgd-
deficient Treg cells and WT littermate control animals to HFD feeding for 15 weeks. There 
was no difference in the composition of the VAT-resident immune-cell compartment between 
WT mice and mice with Hpgd-deficient Treg cells after HFD feeding. While we do observe an 
increase in the Treg cell population per gram of VAT, this difference could be explained by the 
difference in VAT weight rather than by a difference in the absolute number of Treg cells. 
Furthermore, no difference in the macrophage population could be observed. This could be 
explained by the inherently pro-inflammatory state induced by subjecting animals to HFD. 
Through feeding of a HFD, we elicit a proinflammatory state in both WT and KO animals, 
thus possibly obfuscating the inherent difference in the inflammatory state of these animals. 
Moreover, while we were able to detect a small decrease in insulin sensitivity in the 
deficient animals after 15 weeks of HFD feeding, this difference was much less pronounced 
than in the aged animals. This may be explained by the fact that HFD feeding worsens 
metabolic parameters also in WT animals (Ingvorsen et al., 2017) and thus the difference 
between KO and WT animals is decreased. Furthermore, while there does seem to be a trend 
in KO and WT animals after ND feeding, the decrease in insulin sensitivity in the KO animals 
is not statistically significant. This may be due to the relatively young age of the animals since 
under steady-state conditions we could only detect a difference in aged animals. It is possible 
that we would have observed a more pronounced difference in the metabolic state and the 
VAT-resident immune-cell compartment, had we prolonged the feeding until the animals 
reach around 40 weeks of age. 
5.4. Intrinsic vs. extrinsic functionality of Hpgd 
Loss of Hpgd in Treg cells leads to a variety of different effects in aged animals, 
including a dysregulation of the metabolism and immune-cell homeostasis in the VAT, 
including an increase in the Treg cell population and an upregulation of the proliferative 
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marker Ki-67. There are two different explanations for the effects observed: either the 
changes are intrinsic, i.e. the deletion of Hpgd in Treg cells changes the Treg cell transcriptional 
profile leading to decreased suppressive capacities and an increase in the proliferation of the 
cells, or extrinsic in nature and caused by the loss of the enzymatic activity of Hpgd. 
However, these two modes of action are not mutually exclusive and have been 
previously described with other molecules of the Treg cell signature. A deletion of the co-
stimulatory molecule CD28 on Treg cells was shown to induce both intrinsic and extrinsic 
defects in Treg cell functionality. On the one hand, intrinsic CD28 signaling is vital to maintain 
the peripheral Treg cell pool (Gogishvili et al., 2013) while on the other hand a deletion in 
CD28 affects the CD25 expression on Treg cells (Tang et al., 2003), thus influencing Tconv cell 
IL-2 deprivation, one of the major methods through which Treg cells confer suppressive 
capabilities, in an extrinsic manner.  
When we analyzed the transcriptome of splenic Treg cells, we could not detect a 
difference in the Treg cell signature caused by the deletion of Hpgd in Treg cells. Similarly, the 
VAT-resident Treg cell signature remained unaffected by the loss of Hpgd, with the exception 
of a downregulation of Entdp1. Entdp1 is also known as CD39 and is the rate-limiting ecto-
enzyme which hydrolyses the pro-inflammatory ATP into the anti-inflammatory derivate 
adenosine (Zhao et al., 2017), which has been described as an important suppressive 
mechanism in the plethora of Treg cell suppressive mechanisms.. Thus, it is tempting to 
speculate that a downregulation of Entdp1 in VAT-resident Treg cells caused by a deletion of 
Hpgd further impairs Treg cell function and contributes to increased inflammation. However, 
these subtle changes in the VAT-resident Treg cell signature did not affect either metabolic or 
immunological pathways, as shown by gene ontology enrichment analyses, thus indicating 
that a loss of Hpgd does not affect the cells intrinsically and that the observed effects are 
mainly caused by the loss of the enzymatic function of Hpgd. 
Furthermore, when we analyzed the effect of a loss of Hpgd on the proliferation of 
adoptively transferred Hpgd-deficient and sufficient Treg cells, we could not detect a 
difference in their proliferation, indicating that the increased Treg cell population in the VAT 
of aged animals is not caused by an altered competitive fitness further indicating that the 
observed changes caused by the loss of Hpgd are extrinsic in nature. 
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5.5. Role of HPGD in Treg cells of T2D patients 
In human T2D patients, we found a dysregulation of the Treg cell population in 
peripheral blood. In two microarray datasets, analyzed by linear support vector regression 
(SVR), the signature from the Treg cell fraction was decreased in whole blood transcriptome 
data from T2D patients while in flow cytometric data we could observe an increased ratio of 
Treg cells to Tconv cells in T2D patients compared to healthy control patients. However, this 
apparent incongruity can be explained by the two different analysis approaches: for the 
microarray datasets, we analyzed the Treg cell fraction in comparison to the entire immune-cell 
compartment of the patients and could observe that most immune cell types were dysregulated 
in T2D patients compared to healthy individuals. Thus any changes observed are only relative 
changes within the immune cell compartment. Meanwhile, when analyzing the Treg cell 
fraction by flow cytometry, we could observe an increase in the Treg cell fraction, which was 
also reflected in murine Hpgd-deficient VAT-resident Treg cells isolated from aged animals. 
Further, we could show that the HPGD expression in Treg cells isolated from T2D 
patients is significantly decreased compared to the HPGD level in Treg cells isolated from 
healthy individuals in two distinct datasets. Considering that we could show that HPGD 
confers a more suppressive phenotype to Treg cells, this indicates that Treg cells of T2D are less 
immunosuppressive. This is compatible with the general proinflammatory phenotype of T2D 
patients (Donath and Shoelson, 2011) and seems to indicate that HPGD expression in Treg 
cells might play a role in T2D. Moreover, T2D has been historically treated with anti-
inflammatory drugs to ameliorate metabolic symptoms of the disease (Williamson, 1901; 
Yuan et al., 2001), thus showing that the disease progression may be affected by modulating 
Treg cell functionality, for instance by augmenting HPGD levels. However, whether the 
downregulation of HPGD in Treg cells of T2D patients is a cause or an effect of T2D remains 
unclear. It has been described that different signaling pathways are affected by the onset of 
T2D due to an alteration in, for example, glucose or insulin levels leading to global changes in 
the transcription profile in different cell types, including TH cells (Ganeshan and Chawla, 
2014; Hall et al., 2018). Furthermore, it has been shown that, in response to environments low 
in nutrients, Foxp3 can reprogram Treg cells to adapt them to better utilize the available 
nutrients (Angelin et al., 2017). This indicates that FOXP3 signaling, which is upstream of 
HPGD, can be affected by a dysregulation of the cellular metabolism and could therefore lead 
to a decrease in HPGD levels caused by the development of T2D. Conversely, it has also been 
shown that FOXP3 is vital for metabolic homeostasis, as a FOXP3 mutation which does not 
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lead to any of the typical IPEX symptoms, caused neo-natal diabetes (Hwang et al., 2018). 
Thus, it is also credible that a dysregulation of the Treg cell signature leading to a reduction in 
Treg cell functionality could be one of the factors contributing to the development of T2D. 
Another indication that increased HPGD levels may be beneficial in T2D is the 
observation that the activation of Ppar-γ signaling has been shown to increase insulin 
sensitization in mice (Cipolletta et al., 2012). Furthermore, treatment with Ppar-γ agonists has 
been shown to expand the VAT-resident Treg cell population, thereby improving metabolic 
parameters and decreasing inflammation (Cipolletta et al., 2012). Furthermore, PPAR-γ 
agonists have been used to treat T2D (Savkur and Miller, 2006). Thus, increased Treg cell 
HPGD levels, leading to an increased presence of 15-keto-PGE2 and increased Ppar-γ 
signaling may be beneficial in combating metabolic dysregulation, such as T2D. 
5.6. The role of MEOX1 in Treg cells 
In an effort to better understand the underlying transcriptional program of Treg cells, 
we further analyzed the transcription factor MEOX1, which we could show to be upregulated 
in all Treg cell conditions we analyzed in a similar manner to HPGD. Furthermore, MEOX1 
and HPGD can be found in the same WGCNA module, suggesting a common mechanism of 
regulation. Indeed, both HPGD and MEOX1 are upregulated in response to IL-2 stimulation 
and both can be downregulated by an siRNA-mediated knock-down of FOXP3. Due to these 
commonalities in their regulation, we further attempted to analyze whether the transcription 
factor MEOX1 can influence HPGD expression. However, knocking down MEOX1 in an 
siRNA mediated manner did not influence HPGD or FOXP3 expression in human Treg cells. 
We therefore conclude that MEOX1 is not directly involved in the regulation of 
HPGD expression. However, it would be interesting to determine whether MEOX1 influences 
either Treg cell functionality or the Treg cell signature, since it has been previously published 
that while the transcription factor FOXP3 is lineage defining for Treg cells and central for both 
Treg cell functionality and transcription, it is not the sole factor responsible for Treg cell 
differentiation (Ohkura et al., 2012; Sawant and Vignali, 2014). Furthermore, induction of 
FOXP3 expression is not sufficient to completely establish the Treg cell signature and vice 
versa the Treg cell signature can be partially induced even in the absence of FOXP3 (Hill et al., 
2007; Lin et al., 2007). This is all indicative that there are other factors, next to FOXP3, 
which control Treg cell differentiation and the Treg cell signature, such as the genome organizer 
Satb1 (Beyer et al., 2011) or the transcription factors NFAT and Smad3 (Tone et al., 2008) . 
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MEOX1, in its role as a transcription factor which is significantly upregulated across most 
Treg cell conditions, could play a role in this induction of the Treg cell signature. 
5.7. Model of HPGD action for the suppressive functionality of Treg cells 
All in all, we propose a new role for HPGD for Treg cell dependent suppression of 
other immune cells in a tissue-specific manner: HPGD metabolizes PGE2 into the PPAR-γ 
ligand 15-keto-PGE2 which leads to the inhibition of Tconv cell activation which is at least 
partially mediated through PPAR-γ signaling. Furthermore, a Treg cell specific deletion of 
Hpgd leads to increased visceral adipose tissue inflammation in aged animals, most likely 
caused by the loss of suppressive function in VAT Treg cells. This increased inflammation is 
characterized by an accumulation of non-functional Treg cells, NK cells and proinflammatory 
macrophages as well as a decrease in insulin and glucose sensitivity and an increased HOMA-
IR (summarized in Figure 51). Thus, we could show that HPGD in Treg cells is not only 
important for the suppressive function of Treg cells but also for maintaining VAT homeostasis 
through the regulation of PGE2 levels. 
 
Figure 51: Model for the role of HPGD in Treg cell mediated suppression. 
Hpgd metabolizes PGE2 into the suppressive metabolite 15-keto-PGE2. A loss of murine 
Hpgd is implicated in the spontaneous development of a metabolic syndrome, an 
accumulation of VAT-resident Treg cells and proinflammatory macrophages in aging animals.  
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7. Appendix 
 
Figure 52: Schematic representation of mouse constructs. 
A) Hpgd locus: Exon 1 of the Hpgd locus is flanked by two loxP sites to allow for the 
selective deletion of Hpgd by crossing of the line to a line expressing a Cre-recombinase 
(Roizen et al., 2008) B) Ppar-γ locus: Exon 2, containing the DNA binding domain, is 
flanked by two loxP sites, allowing for the deletion of Ppar-γ upon crossing with animals 
expressing a Cre-recombinase (Akiyama et al., 2002) C) Foxp3 locus: A YFP-Cre construct is 
inserted into the 3’ UTR of the Foxp3 locus under the control of an IRES site. (Rubtsov et 
al., 2008) D) CD4 locus: a construct containing an independent TSS followed by a Cre-
recombinase is inserted proximal to the CD4 promoter (Lee et al., 2001) E) Rag-2 locus: 
the Rag-2 coding region was replaced with a Neo-Poly A cassette (Shinkai et al., 1992). 
UTR, untranslated region; IRES, internal ribosomal entry site; YFP, yellow fluorescent 
protein; TSS, transcriptional start site. 
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8.  Zusammenfassung 
Regulatorische T-Zellen (Treg-Zellen) sind essentiell für die Aufrechterhaltung der 
Immunhomöostase. Wie Treg-Zellen ihre Funktion in unterschiedlichen Geweben ausüben, ist 
jedoch oft unbekannt. Wir haben festgestellt, dass Hydroxyprostaglandin Dehydrogenase 
(Hpgd), ein Enzym welches Prostaglandin E2 (PGE2) metabolisiert, in Treg-Zellen im 
Vergleich zu konventionellen T-Zellen signifikant hochreguliert ist, sowohl beim Menschen 
als auch in der Maus. In der Maus ist dies besonders im viszeralen Fettgewebe, einem 
Prostaglandin-reichen Organ der Fall.  
Darüber hinaus konnten wir zeigen, dass Hpgd durch den Metabolismus von PGE2 zu 
15-keto-PGE2 die suppressiven Fähigkeiten von Treg-Zellen, in einer zumindest teilweise 
Pparγ-abhängigen Art, verstärkt. In vivo konnten wir zeigen, dass Hpgd-defiziente Treg Zellen 
das Auftreten induzierter Colitis weniger effizient hemmen als Hpgd-kompetente Treg Zellen. 
Dies weist darauf hin, dass Hpgd eine Rolle in der Suppressionsfähigkeit von Treg Zellen 
spielt. Transkriptionell unterscheiden sich Hpgd-defiziente Treg Zellen und wildtypische Treg 
Zellen jedoch kaum. Dies deutet darauf hin, dass die beobachteten Unterschiede auf den 
extrinsischen Effekt zurückzuführen sind, welcher durch den Verlust der enzymatischen 
Funktion von Hpgd hervorgerufen wird. 
Bei der Analyse des viszeralen Fettgewebes alter Tiere mit Hpgd-defizienten Treg 
Zellen konnten wir eine Anreicherung von nicht-funktionellen Treg Zellen sowie eine 
Ansammlung aktivierter Makrophagen und eine signifikante Vergrößerung der Adipozyten 
nachweisen. Obwohl wir keine Veränderung im Körpergewicht oder im Spontanverhalten, 
d.h. in der Motilität, in der Nahrungs- und Wasseraufnahme oder in der Atmung, dieser Tiere 
feststellten, konnten wir eine Fehlregulation des Metabolismus beobachten: Alte Mäuse mit 
Hpgd-defizienten Treg-Zellen reagieren weniger auf Insulin- und Glukose. Des Weiteren 
scheint in den Tieren die Insulinsignalkaskade teilweise inhibiert zu sein. 
Werden Tiere mit Hpgd-defizienten Treg-Zellen einer Fütterung mit hochkalorischem 
Futter unterzogen, kommt es zu einer verminderten Reaktion auf Insulin im Vergleich zu 
wildtypischen Tieren auf gleicher Diät. Ansonsten haben wir jedoch keinen Unterschied in 
der Gewichtszunahme, in anderen metabolischen Parametern oder in den im viszeralen 
Fettgewebe ansässigen Immunzellen beobachten können. 
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Des Weiteren konnten wir im Blut von Patienten mit Typ-II-Diabetes (T2D) eine 
Fehlregulation der Treg-Zellpopulation sowie eine verminderte HPGD-Expression in diesen 
Zellen identifizieren. Zusammengefasst zeigen diese Daten, dass sowohl beim Menschen als 
auch in der Maus die HPGD-Expression in Treg-Zellen an der metabolischen Regulation 
beteiligt sein könnte. 
Schließlich analysierten wir die Rolle des Treg-Zell-spezifischen Transkriptionsfaktors 
Mesenchym Homeobox 1 (MEOX1) in der Expression von HPGD und konnten nachweisen, 
dass MEOX1 in humanen Treg-Zellen hochreguliert ist, besonders nach Stimulation mit 
Interleukin (IL) 2. Darüber hinaus konnten wir zeigen, dass die MEOX1-Expression in 
humanen Treg Zellen zwar wie die Expression von HPGD durch FOXP3 reguliert wird, der 
Verlust von MEOX1 jedoch die HPGD-Expression nicht beeinflusst. Dadurch widerlegten 
wir unsere Hypothese, dass HPGD von MEOX-1 reguliert wird. 
Zusammenfassend konnten wir zeigen, dass die Expression von HPGD in Treg Zellen 
sowohl im murinen System als auch beim Menschen ein wichtiger Mediator der 
Suppressionsfähigkeit ist, unabhängig von MEOX1. Des Weiteren konnten wir nachweisen, 
dass eine Treg-Zell-spezifische Deletion von Hpgd in der Maus zu einer Fehlregulation des 
Metabolismus führt. Dieses Phänomen spiegelt sich im Menschen in T2D-Patienten wieder, 
da hier die HPGD-Level in Treg-Zellen aus dem peripheren Blut signifikant reduziert sind. 
  
  
133 
 
9. Publication  List 
 
Schmidleithner, L., Thabet, Y., Schönfeld, E., Köhne, M., . . . Schultze, J.L., Beyer, M. Enzymatic 
Activity of HPGD in Treg Cells Suppresses Tconv Cells to maintain Adipose Tissue Homeostasis and 
Prevent Metabolic Dysfunction. Immunity; doi:10.1016/j.immuni.2019.03.014 
Beyer, M., Abdullah, Z., Chemnitz, J. M., . . . Schmidleithner, L., . . . Schultze, J. L. (2016). Tumor-
necrosis factor impairs CD4 T cell–mediated immunological control in chronic viral infection. Nat 
Immunol, 17(5), 593-603. doi:10.1038/ni.3399 
Xue, J., Schmidt, S., Sander, J., . . . Schmidleithner, L., . . . Schultze, J.L. (2014). Transcriptome-
Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation. Immunity, 
40(2), 274-288. doi:10.1016/j.immuni.2014.01.006 
 
